 
 
 
 
 
 
 
 
  
 
 
[STUDY_ID_REMOVED] 
 
 
 
 Pediatric Cardiac O utput Monitorin G Observational Study  
 
 (POGO Study ) A Prospective, Single -Arm, Nonrandomized, 
Observational Study of Cardiac Output Monitoring in 
Pediatric Patients  
 
 
Clinical Trial Protocol and Statistical Analysis Plan  
 
 
Clinical Trial Protocol version : Novem ber 20, 2022  
Statistical Analysis Plan  version: December 2, 2020  
 
 
 
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 1of 52 CONFIDENTIAL
Pediatric Cardiac Output Monitorin GObservational Study
(POGO Study )
A Prospective, Single-Arm, Nonrandomized, Observational Study 
of Cardiac Output Monitoring in Pediatric Patients 
Clinical Study Protocol
Study Number: 2019-08
IDE Number: G190308
Revision: E
Date: November 20, 2020
Edwards Lifesciences LLC
One Edwards Ways
Irvine, CA 92614 USA
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 2of 52 CONFIDENTIAL
Revision B Change Summary
Please note: Punctuation, formatting or cler ical changes are not included in the table.
Section 
(Page)Change and Reason for Change
Synopsis & Study Design
(7 & 17)Updated number of sites to up to 5
Reason: To meet enrollment goal wi thin 12 months of commencement 
Schedule of Events & P rocedures
(26)Removed reference of thermodilutions analyses
Reason: SAP provides details of analysis
Independent Safety Committees 
(36)Clarified the structure of the DSMB meetings
Reason: To ensure it is clear that efforts to mitigate operational bias are in 
place
Revision C Change Summary
Please note: Punctuation, formatting or cler ical changes are not included in the table.
Section 
(Page)Change and Reason for Change
Synopsis, Study Objective & 
Statistical Methods
(8, 16 & 22)Limited secondary effectiveness endpoint to a single focus on CO, as 
determined by the Critchley and Cr itchley method of  percent error 
calculation. Also added exploratory analyses comparisons of CI, as 
determined by the Critchley and Cr itchley method of  percent error 
calculation and CI as determined by the Bland-Altman method of bias.
Reason: To align with revise d statistical analysis plan
Data Safety Monitoring Board
(37)Updated to indicate DSMB’s role in study oversight 
Reason: Clarified that DSMB  will solely evaluate study safety and base its 
recommendation to continue the study on this assessment.  There is no 
planned interim analysis, thus DSMB  will not assess effectiveness.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 3of 52 CONFIDENTIAL
Revision D Change Summary
Please note: Punctuation, formatting or cler ical changes are not included in the table.
Section 
(Page)Change and Reason for Change
Synopsis, Subject Selection and 
Withdrawal(8, 19)Edited inclusion criteria #4 to read “F or those Subjects who have had a 
cardiac transplant, Subjects must be  at least two weeks post cardiac 
transplantation.”
Reason: To qualify and better clar ify that pre-transplant cardiac 
catherization evaluations are a llowable.  For only those S ubjects who have 
undergone cardiac transplantation, thos e Subjects will need to wait at 
least 2 weeks after the transplant to be eligible for the study.
Revision E Change Summary
Please note: Punctuation, formatting or cler ical changes are not included in the table.
Section 
(Page)Change and Reason for Change
Synopsis, Subject Selection and 
Withdrawal(8, 19)Edited exclusion criteria to include the following additional exclusions: 
6. Documented ≥ moderate pulmonary hypertension (PAPm > 25 mmHg , 
PVRI > 3.0 WUxm2)
7. Presence of intracardiac  shunting (i.e., ASD, VSD)
8. Aorto-pulmonary collaterals 9. ≥ Moderate tricuspid regurgitatio n, per echocardiogram criteria
10. > Moderate Aortic or pulmonary regurgitation, per echocardiogram 
criteria11. Persistent cardiac arrythmias during the cardiac catheterization
period 
(> 3min)
12. Vascular abnormalities of the arteri al system (i.e., connective tissue 
disorders, mid-aortic syndrome)
Reason: Additional clarity to ensure inte nded exclusion of patients whose 
path ophysiologic state may result in in termittent and/or prolonged states 
in which the cardiac outp ut from the right side of the heart may differ 
from the cardiac output from the left side of the heart.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 4of 52 CONFIDENTIAL
INVESTIGATOR’S SIGNATURE PAGE
This study will be carried out in accordance with In ternational Conference on Harmonisation Good Clinical 
Practice (ICH GCP) and 21 CFR Parts 11, 50, 54, 56 and 812.
I will provide copies of the protocol to the Institutional Review Board and all members of the Study team 
responsible to me who participate in the Study.  I w ill discuss this material with them to ensure that all 
participating personnel at the St udy site are fully informed regarding the conduct of the protocol.
Once the Institutional Review Board approves the protoc ol, I will not modify this protocol without obtaining 
the prior approval of both the Sponsor and the Instit utional Review Board.  I will submit the protocol 
modifications and/or any informed consent modification s to the Sponsor and the Institutional Review Board, 
as applicable, and approval will be obtained before any modifications are implemented.
I will conduct the study as detailed in the protocol and in accordance with conditions of the approval imposed 
by the Institutional Review Board and all applic able regulations. I will maintain adequate source 
documentation records throughout the study and make th em available as requested during monitoring visits.  
I will maintain device accountability records and will supervise the used of the device involving human subjects. In addition, I will provide all the informat ion requested in the electronic Case Report Forms 
presented to me by the Sp onsor in a manner to assure completeness and accuracy.
I will ensure that the requirements for obtaining inform ed consent are met. Additionally, I will disclose 
financial interests in accordance with 21 CFR 54, and certify that such financial interests, if any, will not 
interfere with my responsibilities as an investigator or influence study outcomes under my supervision.
I have read the attached protocol and hereby agree that it contains all the necessary details for performing 
the Study. 
Investigator's Signature Date
Investigator’s Printed Name
Study Site Name
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 5of 52 CONFIDENTIAL
Table of Content
Synopsis ............................................................................................................................... ....................... 8
1. Introduction ............................................................................................................................... .......... 10
Background ............................................................................................................................... ......................................10
2. Medical Devices ............................................................................................................................... ... 12
Device Names ............................................................................................................................... ..................................12
Device Descriptions, Contraindications and Intended Uses ....................................................................................12
Swan-Ganz Technology ............................................................................................................................... .....................12
FloTrac Technology ............................................................................................................................... .............................13
ClearSight Technology ............................................................................................................................... ........................14
ForeSight Elite Technology ............................................................................................................................... ................15
3. Study Objective ............................................................................................................................... .... 17
Study Endpoints ............................................................................................................................... ..............................17
4. Study Design ............................................................................................................................... ........ 18
General Design ............................................................................................................................... ................................18
5. Subject Selection and Withdrawal ................................................................................................... 19
General Characteristics of the Proposed Subject Selection ....................................................................................19
Informed Consent ............................................................................................................................... ............................19
Inclusion Criteria ............................................................................................................................... ..................................19
Exclusion Criteria ............................................................................................................................... .................................19
Subject Screening ............................................................................................................................... ...........................20
Early Withdrawal of Subjects ............................................................................................................................... .............20
6. Statistical Methods ............................................................................................................................. 21
Primary Effectiveness Endpoint ............................................................................................................................... ....21
Sample Size Justification ............................................................................................................................... ...............21
Primary Safety Endpoint ............................................................................................................................... .................23
Analysis Populations ............................................................................................................................... .......................23
Analysis Methods ............................................................................................................................... ............................23
Secondary Effectiveness Endpoint ..............................................................................................................................2 3
Additional Evaluations ............................................................................................................................... ....................23
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 6of 52 CONFIDENTIAL
7. Receiving, Storage, and Return of devices .................................................................................... 25
Receipt of Device Supplies ............................................................................................................................... ............25
Storage ............................................................................................................................... .............................................25
Device Accountability ............................................................................................................................... ......................25
Return of Device ............................................................................................................................... ..................................25
8. Schedule of Events & Procedures ................................................................................................... 26
Schedule of Events ............................................................................................................................... .........................26
Intermittent Thermal Dilution Assessment(s) .............................................................................................................27
Clinical Study Completion or Early Termination ........................................................................................................27
Protocol Deviation ............................................................................................................................... ...........................27
Changes to the Protocol ............................................................................................................................... .................29
9. Risk Analysis ............................................................................................................................... ........ 30
Anticipated Risks ............................................................................................................................... .............................30
Risk Management ............................................................................................................................... ...........................32
Benefits ............................................................................................................................... .................................................32
10.Reportable Events .............................................................................................................................. 3 3
Recording and Reporting of Adverse Events .............................................................................................................33
Recording and Reporting of Adverse Device Effects ................................................................................................33
Recording and Reporting of Serious Adverse Event ................................................................................................34
Recording and Reporting of Serious Adverse Device Effects .................................................................................34
Recording and Reporting of Unanticipated Adverse Device Events ......................................................................34
Recording and Reporting of Deaths ............................................................................................................................35
Recording and Reporting of Adverse Events  Associated with Commercial Components ..................................35
Recording and Reporting of Pre-Existing Conditions ................................................................................................35
Reporting Adverse Events to the FDA ........................................................................................................................35
Reporting Adverse Events to the Responsible IRB ...................................................................................................36
11.Independent Safety Committees ...................................................................................................... 37
Clinical Events Committee ............................................................................................................................... .............37
Data Safety Monitoring Board ............................................................................................................................... .......38
Stopping Rules ............................................................................................................................... .....................................38
12.Data Handling and Record Keeping ................................................................................................ 39
Confidentiality ............................................................................................................................... ..................................39
Source Documents ............................................................................................................................... ..........................40
13.Data Collection Methods ................................................................................................................... 41
14.Record Retention ............................................................................................................................... .4 2
15.Study Documentation ........................................................................................................................ 43
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 7of 52 CONFIDENTIAL
Study Records ............................................................................................................................... .................................43
Study Reports ............................................................................................................................... ..................................43
Communication Procedures ............................................................................................................................... ..........45
16.Study Monitoring, Auditing and Inspecting ................................................................................... 46
Site Selection ............................................................................................................................... ...................................46
Study Monitoring Plan ............................................................................................................................... .....................46
Interim Monitoring Activities ............................................................................................................................... ...............46
Site Close-Out Visit ............................................................................................................................... .............................46
Auditing and Inspecting ............................................................................................................................... ..................47
17.Ethics ............................................................................................................................... ..................... 48
Ethical and Scientific Conduct of the Clinical Research Study ................................................................................48
18.Financial Disclosures ......................................................................................................................... 49
19.Publications ............................................................................................................................... .......... 50
20.Acronyms and Abbreviations ........................................................................................................... 51
21.References ............................................................................................................................... ............ 52
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 8of 52 CONFIDENTIAL
SYNOPSIS
Title: P ediatric Cardiac Output Monitorin GObservational Study
Short Title: POGO Study
Study 
Objective:The primary objective of the study is to assess Cardiac Output Monitoring in 
pediatric subjects by comparing FloTrac and ClearSight system to intermittent thermodilution Swan-Ganz, 
in order to expand the indications 
of FloTrac, ClearSight and Swan-Ganz thermodilution pulmonary artery 
catheter to the pediatric population 12 to 18 years of age.  
Study Devices:HemoSphere advanced monitoring plat form, intermittent thermodilution 
Swan-Ganz, FloTrac, ClearSight system, ForeSight Elite sensors
Overall Design:A prospective, single-arm, nonrandomized, observational study to assess the cardiac output (CO) monitoring methods in pediatric subjects.
Study Population: Up to 108 eligible Subjects in a single armMales and Females, 12 to 18 years of age at the time of screening.
Number of Sites:Up to five (5) U.S. sites
Study Duration:Total of 9 to 12 months
ParticipationDuration:Screening/Baseline; Procedure; 30-day Telephone Follow-Up Visit
Inclusion/ 
Exclusion Criteria:Inclusion Criteria
1. Subjects who are 12 to 18 years of age2. Subjects who have signed the Informed Consent Form3. Subjects who are projected to receive Swan-
Ganz catheter as part of 
procedure/standard of care with intermittent cardiac output measures
4. For those Subjects who have had a cardiac transplant, Subjects must 
be at least two weeks post cardiac transplantation
5. Subjects with planned pressure mo nitoring with an arterial line  
Exclusion Criteria
1. Subjects with contraindications for Pulmonary Artery Catheters 
Placement and monitoring (recurrent sepsis, or with 
hypercoagulopathy) ;
2. Subjects with contraindications for Arterial Line Placement;
3. Subjects with an extreme contraction of the smooth muscle in the 
arteries and arterioles in the lower arm and hand (i.e., Raynaud’s Disease).
4. Subjects with a physical site area too limited for proper Sensor 
placement
5. Subjects with finger size less than the smallest finger cuff size
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 9of 52 CONFIDENTIAL
6. Documented ≥ moderate pulmonary hyp ertension (PAPm > 25mmHg, 
PVRI > 3.0 WUxm2)
7. Presence of intracardiac shunting (i.e., ASD, VSD)
8. Aorto-pulmonary collaterals 9.≥ Moderate tricuspid regurgitati on, per echocardiogram criteria
10. > Moderate Aortic or pulmonary regurgitation, per echocardiogram
criteria
11. Persistent cardiac arrythmias during the cardiac catheterization 
period (> 3min)
12. Vascular abnormalities of the arterial system (i.e., connective tissue 
disorders, mid-aortic syndrome)
Primary Effectiveness Endpoint: Demonstrate that monitoring of cardiac output with Swan-Ganz, FloTrac, 
and ClearSight system is comparable as determined by the Bland-Altman 
method of bias.
Primary Safety 
Endpoint:The primary safety endpoint is to assess all serious intraoperative and post-
operative adverse events through 30 days, including serious device- related 
events.
SecondaryEffectiveness Endpoint: Demonstrate that monitoring of cardiac output with Swan-Ganz, FloTrac, and 
ClearSight system is comparable as determined by the Critchley and Critchley 
method of percent error calculation.
Study Sponsor:Edwards Lifesciences LLC
One Edwards Way
Irvine, CA 92614 USA
Study Director:
 
 
Study Manager:
 

     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 10of 52 CONFIDENTIAL
1. INTRODUCTION
Background
In the critically ill, traditional vital signs may be late indicators of compromised or inadequate oxygen delivery 
to the tissues, potentially delaying intervention and putting the patient at greater risk. The ability to monitor 
blood oxygenation early is critical. The pursuit of meas uring blood flow through the heart has resulted in the 
development of different techniques for its quantificat ion. The three main methodol ogies to measure cardiac 
output are the Fick method, dye dilu tion, and thermodilution techniques[9]. The Fick method is the “gold 
standard” for cardiac output determinations in adults and is based on the principles developed by Adolph Fick in the 1870’s. Fick’s concept proposes that the uptake or release of a substance by an organ is the product of blood flow through that organ and the difference betw een the arterial and venous values of the same 
substance. The Fick principle reflects the extraction of oxygen through the systemic circulation and is 
dependent on arterial and pulmonary arterial oxygen levels, hemoglobin and the maximum amount of oxygen 
consumption by the body in a given period (VO2 max).  Thus, the Fick principle involves the blood oxygenation 
process through the lungs and oxygen delivery to the ti ssues, where it is added and removed by a flow limited 
mechanism.  By measuring the amount of oxygen carrie d by the blood, the total amount of blood needed to 
carry oxygen through the lungs could be calculated.  This value then reflects the output of the heart
[9].
An intermittent thermodilution method applies the Ste ward Hamilton indicator dilution principles, using
temperature change as the indicator. A known amount of  solution with a known temperature is injected into 
the right side of the circulation and continuously withdr awn and measured at a constant rate from the arterial 
side. This resultant curve is plotted against time and ca rdiac output is calculated using the Stewart-Hamilton 
Equation. This curve is similar to the one produced by  the indicator dilution method. A modified Stewart-
Hamilton equation is used to calculate the cardiac ou tput, taking into consideration the change in temperature 
as the indicator. Modifications include the measured temperature of the injectate and the patient’s blood
temperature, along with the specific gravity of the solution injected[9].
Minimally invasive technologies have been developed to  monitor CO. FloTrac is a minimally invasive solution 
for advanced hemodynamic monitoring that automatically calculates key flow parameters every 20 seconds. Continuous clarity provided by the FloTrac system off ers proactive decision support to manage hemodynamic 
instability and ensure adequate perfusion. In additi on to minimally invasive technologies, noninvasive 
technologies such as the ClearSight system offer proactive decision support to optimize perfusion. The ClearSight system provides advanced hemodynamic pa rameters and continuous noninvasive blood pressure 
(BP) from a finger cuff and extends the benefits of continuous hemodynamic monitoring to a broad patient 
population, including patients in whom an ar terial line would not typically be placed
[10].
The Swan-Ganz pulmonary artery catheter (PAC) is considered  the gold standard to validate new CO monitoring 
devices. The Swan-Ganz PAC consists of an intravenou s device placed in the pulmonary artery allowing 
measurement of cardiac output, pulmonary artery pressures [1]as well as cardiac filling pressures. Since its 
initial presentation by Swan in 1970 [2], several modifications were made on the initial catheter that allowed 
for intermittent monitoring of cardiac output, stroke vo lume (SV), systemic vascular resistance (SVR) and mixed 
venous saturation (SvO 2) [1,3]. Technology for cardiac output (CO) and blood volume measurements has been 
developed using existing central venous and peripheral arterial catheters (PAC), such that 
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 11of 52 CONFIDENTIAL
transcardiopulmonary thermodilution of blood with a sm all saline bolus is detected with ultrasound sensors 
attached to an extracorporeal arteriovenous loop [4].  
There is an unmet need in the pediatric population, as th ere are currently no clinically practical, accurate or
precise methods for measuring cardiac output (CO).  During his research in 1920, Alfred Blalock, M.D., a pioneer 
of pediatric congenital cardiac surgery found that “the repeated removal of blood is usually associated with a decline in the cardiac output from 30 to 50% below th e normal level before a marked diminution in the mean 
blood pressure occurs”
[4,5].  Even though it has been nearly 100 years since Dr. Blalock demonstrated the 
importance of cardiac output in global cardiovascular circulation, even with its shortcomings, blood pressure 
remains the gold standard for hemodynamic monitoring of cardiovascular function in critically ill pediatric 
patients[6]. Cardiac output is measured very rarely in the pediatric population; however, it is vital for oxygen 
delivery.  In this population, the methods used for cardia c output monitoring continue to be a poor surrogate, 
not validated or inaccurate. Cardiac output measurem ent is an essential part of hemodynamic monitoring and 
management of all critically ill patients, including pediatric patients of all ages and sizes[7].  
The primary objective of the study is to assess Cardiac Output Monitoring in pediatric subjects by comparing 
FloTrac, ClearSight system to intermittent thermodiluti on Swan-Ganz, in order to expand the indications of 
FloTrac, ClearSight and Swan-Ganz th ermodilution pulmonary artery catheter to the pediatric population 12 to 
18 years of age.  The study population will be children  ages 12 to 18 who are at least 2 weeks post cardiac 
transplant.
The ForeSight Elite sensors, which are cleared for pediatric use, will be used in this study with the HemoSphere 
advanced monitoring platform to collect additional da ta on tissue oximetry. The ForeSight Elite Sensors provide 
the benefit of continually monitoring oxygen s aturation of tissue with accuracy and precision.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 12of 52 CONFIDENTIAL
2. MEDICAL DEVICES
Device Names
xHemoSphere Advanced Monitoring Plat form (including ClearSight Module)
xSwan-Ganz thermodilution pulmonary artery catheter
xFloTrac Sensor
xClearSight System (includes pressure controller/wrist unit, Heart Reference Sensor and finger cuff)
xForeSight Elite Sensors (commercially available in adults and pediatric populations)
Device Descriptions, Contraindications and Intended Uses
Swan-Ganz Technology
Description
The Swan-Ganz thermodilution catheters provide diagnostic information to rapidly determine 
hemodynamic pressures and cardiac output when us ed with a compatible cardiac output computer. The 
Swan-Ganz technology will be used for the intermittent cardiac output measurements. There will be two sets of four repeated intermittent cardiac output measurements.
xSwan Ganz Thermodilution Catheters: K160084 clea red in adults. Devices are investigational in 
pediatric population.
Swan-Ganz Thermodilution Pulmonary Artery Catheter Cleared Indications
The Swan -Ganz thermodilution catheters are indicated for the assessment of a patient’s hemodynamic 
condition through direct intracardiac and pulmon ary artery pressure monitoring, cardiac output 
determination, and for infusing solutions.
The distal (pulmonary artery) port also allows samp ling of mixed venous blood for the assessment of 
oxygen transport balance and the calculation of derive d parameters such as oxygen consumption, oxygen 
utilization coefficient, and intrapulmonary shunt fraction.
Swan-Ganz Thermodilution Pulmonary Art ery Catheter Proposed Indications
Swan-Ganz thermodilution catheters are indicated for the assessment of a patient’s hemodynamic 
condition through direct intracardiac and pulmon ary artery pressure monitoring, cardiac output 
determination, and for infusing solutions.
The distal (pulmonary artery) port also allows samp ling of mixed venous blood for the assessment of 
oxygen transport balance and the calculation of derive d parameters such as oxygen consumption, oxygen 
utilization coefficient, and intrapulmonary shunt fraction .  Indicated for use in adults and pediatric patients 
12-18 years of age.
Contraindications
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 13of 52 CONFIDENTIAL
No absolute contraindications to the use of flow-di rected pulmonary artery catheters exist. However, a 
patient with a left bundle branch block may develop a right bundle branch block duri ng catheter insertion, 
resulting in complete heart block.
HemoSphere Advanced Monitor with HemoSp here Swan-Ganz Module Cleared Indications
The HemoSphere advanced monitor when used with  the HemoSphere Swan-Ganz module and Edwards 
Swan-Ganz catheters is indicated for use in adult and pedi atric critical care patients requiring monitoring of 
cardiac output (continuous [CO] and intermittent [iCO]) and derived hemodynamic parameters in a 
hospital environment. It may be used for monitori ng hemodynamic parameters in conjunction with a 
perioperative goal directed therapy protocol in a hospital environment.
The are no changes to the HemoSphere Advanced Mo nitor with HemoSphere Swan-Ganz Module since the 
specific patient population  indications are provided  as part of the Swan-Ganz catheter IFU (see below).
FloTrac Technology
Description
The FloTrac sensor is a sterile, single use kit that mo nitors pressures when attached to pressure monitoring 
catheters. When connected to a compatible monitor, the FloTrac sensor minimally-invasively measures 
cardiac output and key hemodynamic parameters, whic h assist the clinician in assessing the patient’s 
physiologic status and support clinical decisions re lated to hemodynamic optimization. The disposable 
sterile cable with a red connector interfaces exclusivel y with an Edwards cable that is specifically wired for 
the pressure monitor being used. The disposable sterile  cable with a green connector interfaces exclusively 
with the Edwards cables for use with the Edwards ar terial pressure based cardiac output monitoring 
devices or hardware. The cardiac output measurements  from the FloTrac technology will be compared to 
the intermittent cardiac output measurements from the Swan-Ganz technology.
The FloTrac sensor has a straight, flow-through design across the pressure sensors with an integral flush 
device.
xFloTrac Sensors (classic): K152980 are cleared in adults. Devices are investigational in pediatric 
population.
FloTrac Sensor Cleared Indications
The FloTrac sensor is indicated for use in intravascular pressure monitoring. It is also indicated for use with 
the Edwards arterial pressure based cardiac output monitoring devices or hardware to measure cardiac 
output. 
FloTrac Sensor Proposed Indications
The FloTrac sensor is indicated for use in intravascular pressure monitoring. It is also indicated for use with 
the Edwards arterial pressure based cardiac output monitoring devices or hardware to measure cardiac 
output. Indicated for adult and pediatric patients 12-18 years of age.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 14of 52 CONFIDENTIAL
Contraindications
There are no absolute contraindications for using the FloT rac sensor in patients requiring invasive pressure 
monitoring.
The FloTrac Sensors are cleared for use with th e HemoSphere Advanced Monitor with HemoSphere 
Pressure Cable (K180881).
HemoSphere Advanced Monitor with HemoSphere Pre ssure Cable Cleared Indications (For Use with 
FloTrac)
The HemoSphere advanced monitor when used with the HemoSphere pressure cable is indicated for use in 
critical care patients in which the balance between ca rdiac function, fluid status, vascular resistance and 
pressure needs continuous assessment. It may be us ed for monitoring of hemodynamic parameters in 
conjunction with a perioperative goal directed  therapy protocol in a hospital environment.
The are no changes to the HemoSphere Advanced Mo nitor with HemoSphere Pressure Cable since the 
specific patient population indica tions are provided as part of the FloTrac sensor IFU (see below).
ClearSight Technology
Description
The ClearSight finger cuffs, when used with an appropriate Edwards monitoring system, provide 
continuous, noninvasive hemodynamic monitoring. The ClearSight finger cuffs utilize the volume-clamp 
method to measure blood pressure with an inflatable  bladder wrapped around th e middle phalanx of the 
finger. The cardiac output measurements from the ClearSight technology will be compared to the 
intermittent cardiac output measurements from the Swan-Ganz technology.
xClearSight Finger Cuffs: K190130 are cleared in adults for use with EV1000NI. Investigational device 
for use with HemoSphere Advanced Monitoring Platform.
The ClearSight technology is not cleared in the US for use with the HemoSphere Advance Monitor 
Platform. The non-invasive ClearSight technology is currently available in the US on a different Edwards’ 
platform (EV1000NI - K160552) but is investigati onal on the HemoSphe re advanced monitor.
Contraindications
In some patients with extreme contraction of the smooth  muscle in the arteries and arterioles in the lower 
arm and hand, such as may be present in patients with Raynaud’s disease, blood pressure measurement 
can become impossible.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 15of 52 CONFIDENTIAL
HemoSphere Advanced Monitor with HemoSphere ClearSight Module Proposed Indications
The HemoSphere advanced monitor when used with  the HemoSphere ClearSight module, pressure 
controller and a compatible Edwards finger cuff are indicated for adult patients over 18 years of age and 
pediatric patients 12-18 years of age in which the balance between cardiac function, fluid status and 
vascular resistance needs continuous assessme nt. It may be used for monitoring hemodynamic 
parameters in conjunction with a perioperative goal directed therapy protocol in a hospital environment. 
In addition, the noninvasive system is indicated for use in patients with co-morbidities for which 
hemodynamic optimization is desired and invasive me asurements are difficult. The HemoSphere advanced 
monitor and compatible Edwards finger cuffs noninv asively measures blood pressure and associated 
hemodynamic parameters.
ClearSight Finger Cuff Proposed Indications
The ClearSight finger cuffs are indicated for adult pati ents over 18 years of age and pediatric patients 12-
18 to noninvasively measure blood pressure and as sociated hemodynamic parameters when used with 
EV1000 clinical platform NI or HemoSphere advanced monitoring platform.
The HemoSphere Advanced Monitoring Platform is a multi-parameter, multi-technology, hemodynamic 
platform. The goal of this platform is to provide users with a single point in which they can utilize any of 
Edwards’ hemodynamic disposables. The HemoSphere advanced monitoring platform is composed of a 
primary HemoSphere Monitor.  The HemoSphere advanc e monitoring platform interfaces with external 
technology specific modalities in the form of modul es or Smart-Cables. Each modality is designed to 
connect to a specific type of Edwards disposable product as discussed above, and interface to the 
HemoSphere Monitor via a digital interface.  Th e commercially available HemoSphere Advanced 
Monitoring Platform is cleared for use with the disposables presented above.
ForeSight Elite Technology
Description
The Sensor, when used in combination with the Fore Sight Elite tissue oximeter module or in combination 
with the ForeSight Elite absolute tissue oximeter, is a single use applied part that measures hemoglobin 
allowing the clinician to continuo usly and accurately determine abso lute levels of blood oxygenation 
saturation in the tissue (StO2).
xForeSight Elite Sensors:  K180003, in both pediatric and adult population on the HemoSphere 
Advanced Monitoring Platform (not seeking expansion, only included to obtain additional 
information under its current indications)
ForeSight Elite Sensors (Medium) Cleared Indications
When used in conjunction with the ForeSight Elite absolute tissue oximeter or FORE-SIGHT ELITE tissue 
oximetry module: The medium Sensor is indicated for monitoring of absolute regional hemoglobin oxygen 
saturation of blood under the sensor in individuals at risk for reduced flow or no-flow ischemic states. It is 
intended for use on pediatric subjects ≥ 3 kg.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 16of 52 CONFIDENTIAL
ForeSight Elite Sensors (Large) Cleared Indications
When used in conjunction with the FORE-SIGHT ELITE absolute tissue oximeter or FORE-SIGHT ELITE tissue 
oximetry module: The large Sensor is indicated for monitoring of absolute regional hemoglobin oxygen 
saturation of blood under the sensor in individuals at risk for reduced flow or no-flow ischemic states. It is 
intended for use on pediatric subjects ≥ 40 kg.
There are no proposed indications for  ForeSight Elite technology since Edwards is not seeking indications 
expansion. It is included in the study only to obta in reference information under its currently cleared 
indications for pediatric patients.
Contraindications
The ForeSight Elite sensor is contraindicated for use on patients:
• With a physical site area too limited for proper Sensor placement
• With allergic reactions to Sensor adhesive• Undergoing an MRI scan because of associate risk of injury
The ForeSight sensors are cleared for use with the HemoSphere Advanced Monitor with HemoSphere 
Tissue Oximetry Module (K190205) in both pediatric  and adult population on the HemoSphere Advanced 
Monitoring Platform (not seeking expansion, only included to obtain additional information under its 
current indications)
HemoSphere Advanced Monitor with HemoSphere Tissue Oximetry Module Cleared Indications
The noninvasive ForeSight Elite tissue oximeter module is intended for use as an adjunct monitor of 
absolute regional hemoglobin oxygen saturation of blood under the sensors in  individuals at risk for 
reduced-flow or no-flow ischemic states. The ForeSigh t Elite tissue oximeter module is intended to allow 
for the display of StO2 on the HemoSphere advanc ed monitor.  It is indicated for use as follows:
• When used with large sensors, the ForeSight Elite tissue oximeter module is indicated for use on adults 
and transitional adolescents ≥40 kg.
• When used with medium sensors, the ForeSight E lite tissue oximeter module is indicated for use on 
pediatric subjects ≥3 kg.
• When used with small sensors, the ForeSight Elite tissue oximeter module is indicated for cerebral use 
on pediatric subjects <8 kg and non-c erebral use on pediatric subjects <5kg.
HemoSphere Advanced Monitor with HemoSphere Oximetry Cable Cleared Indications
The HemoSphere advanced monitor when used with the HemoSphere oximetry cable and Edwards
oximetry catheters is indicated for use in adult and pe diatric critical care patients requiring monitoring of
venous oxygen saturation (SvO2 and ScvO2) an d derived hemodynamic parameters in a hospital
environment. Refer to the Edwards oximetry catheter  indications for use statement for information on 
target patient population specific to the catheter being used.  Refer to the Intended Use statement for a 
complete list of measured and derived parameters  available for each patient population.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 17of 52 CONFIDENTIAL
3. STUDY OBJECTIVE
The primary objective of the study is to assess Card iac Output Monitoring in pediatric subjects by 
comparing FloTrac, ClearSight and th e Fick principle (using Swan Ganz ) to intermittent thermodilution 
Swan-Ganz, in order to expand the indications of  FloTrac, ClearSight an d Swan-Ganz thermodilution
pulmonary artery catheter to the pediatric  population 12 to 18 years of age.  
Study Endpoints
The primary effectiveness endpoint is to demonstrate that monitoring of cardiac output (CO) with Swan-
Ganz, FloTrac, and ClearSight is comparable as de termined by the Bland-Al tman method of bias.
The primary safety endpoint is to assess all seriou s intraoperative and post-operative adverse events 
through 30 days, including serious device-related events.
The secondary effectiveness endpoint is to demonstrate that monitoring of cardiac output (CO) with Swan-
Ganz, FloTrac, and ClearSight is comparable as dete rmined by the Critchley and Critchley method of 
percent error calculation.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 18of 52 CONFIDENTIAL
4. STUDY DESIGN
General Design
This study is an observational study in th e U.S. Up to 108 eligible Subjects will be enrolled at up to five (5) 
study sites. A subject will be considered enrolled in  the study once the subject has signed the informed 
consent and a Swan-Ganz thermodilution pulmonary artery  catheter has been deployed, a FloTrac has been 
connected, the ClearSight finger cuff has been attac hed or ForeSight Elite sensors have been placed . The Study 
ID will be a 6-digit number, the first three numbers will  identify the site, and the second set of numbers will 
identify the subject identification number. 
A Swan-Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed 
prior to the start of the catheterization procedure.  Intermittent cardiac output and other hemodynamic
parameters will be collected throughout the duration of the procedure and analyzed according to the Statistical Analysis Plan.
Data collected in this study will support in expanding the current indications of Swan-Ganz, FloTrac and 
ClearSight into the pediatric population.
This study will be conducted in a manner that is consiste nt with the applicable regu lations and in accordance 
with current Good Clinical Practice (GCP).
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 19of 52 CONFIDENTIAL
5. SUBJECT SELECTION AND WITHDRAWAL 
General Characteristics of the Proposed Subject Selection
Subjects 12 to 18 years of age, with planned cathet erization procedure, at least 2 weeks post cardiac 
transplantation, who are projected to receive an art erial line and a Swan-Ganz catheter as part of the 
procedure/standard of care with intermittent cardiac output measures will be screened for inclusion into the Study.  Only subjects meeting all inclusion criteria will be enrolled.  Prior to any Study procedures, an IRB approved informed consent form must be signed and dated by the subject or legal guardian.  Subjects who have been scre ened but do not sign an informed consent form will 
not be considered enrolled and will not have any eCRFs (electronic Case Report Forms) completed.  
Informed Consent
Before a subject undergoes any Study procedures, an informed consent will be obtained utilizing the IRB 
approved consent form.  All consent procedures will be conducted in a manner that is consistent with the applicable regulations and in accordance with Good Clinical Practice (GCP).
During the consent procedure, each potential subject w ill be given ample time to discuss participation in the 
Study and to have any questions or concerns addressed by the Principal Investigator or Investigator.  Each 
subject will be provided with a copy of the IRB approved consent.
Inclusion Criteria
Exclusion Criteria
4. Subjects with a physical site area too limited for proper Sensor placement
5. Subjects with finger size less than the smallest finger cuff size
6. Documented ≥ moderate pulmonary hypertension (PAPm > 25mmHg, PVRI >3.0 WUxm2)
7. Presence of intracardiac shunting (i.e., ASD, VSD)8. Aorto-pulmonary collaterals 9.≥ Moderate tricuspid regurgitati on, per echocardiogram criteria
10. > Moderate Aortic or pulmonary re gurgitation, per echocardiogram criteria
11. Persistent cardiac arrythmias during the catheterization period (> 3min)1. Subjects who are 12 to 18 years of age
2. Subjects who have signed the Informed Consent Form
3. Subjects who are projected to receive Swan- Ganz catheter as part of procedure/standard of care 
with intermittent cardiac output measures
4. For those Subjects who have had a cardiac transp lant, Subjects must be at least two weeks post 
cardiac transplantation
5. Subjects with planned pressure monitoring with an arterial line
1. Subjects with contraindications for Pulmonary Artery Catheters placement and monitoring 
(recurrent sepsis, or wi th hypercoagulopathy) ;
2. Subjects with contraindications for Arterial Line Placement;3. Subjects with an extreme contraction of the smoo th muscle in the arteries and arterioles in the 
lower arm and hand (i.e., Raynaud’s Disease).
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 20of 52 CONFIDENTIAL
12. Vascular abnormalities of the arterial syst em (i.e., connective tissue disorders, mid-aortic 
syndrome)
Subject Screening
All eligible subjects should be screened for Study eligib ility.  The Investigator and/ or Designee(s) at the Study 
site shall review the candidate’s eligibility. The Study site should maintain a cumulative log of all screened 
subjects that are eligible in participating.
Early Withdrawal of Subjects
Subjects may voluntarily withdraw consent at any time during the study with no loss of benefit or penalty. 
The Investigator may withdraw any subject if they de termine that continued participation in the study may 
be detrimental to the subject’s safety and welfare. Each subject withdrawal will be documented on the 
appropriate eCRF. 
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 21of 52 CONFIDENTIAL
6. STATISTICAL METHODS
Primary Effectiveness Endpoint
The primary objective of this study is to demonstrate that monitoring of cardiac output with Sawn-Ganz, 
FloTrac, and ClearSight system is comparable as determined by the Bland-Altman method of bias.
Sample Size Justification
Sample size consideration for bias
The bias between the matched pairs of CO measurem ents, as determined by the Bland-Altman method, 
must be smaller than the minimum clinical difference δ, which is the value that is large enough to claim 
difference. 
The hypothesis for bias is:
  H0:  bias <- δ or bias >δ 
  H1: -δ≤ bias ≤δ 
H0 is the null hypothesis (i.e. the difference between matched pairs of CO values of the two systems is 
larger than δ), H1 is the alternative hypothesis (i.e. the di fference between matched pairs of CO values of 
the two systems is within the range of δ).  A meta-analysis conducted a comprehensive search of 21 
published medical literature to assess the accuracy and precision of minimally invasive CO monitoring 
systems used in children when compared with CO monitoring re ference methods [8]. Among the 21 
studies, 19 studies (90%) showed a bias range of -0.5  to 0.5 L/min. Based on these data, the clinical 
minimum difference δ was set at 0.5 L/min, i.e. bias is expected to be -0.5< bias < 0.5 l/min. This value is 
smaller in magnitude than the 0.8 l/min floor that the US FDA had previously considered for CO 
comparisons. The meta-analysis also shows that 19 out of 21 published studies had standard deviation (SD) 
no more than 1.0 L/min.  
In this study eight repeated measurements (m=8 sub sample s) or sub sample sections will be taken during 
the cardiac catherization case, thus intra-cluster correlation ecoefficiency ICC is a factor to be considered 
in sample size estimation. Here ܥܥܫ=ఋೞమ
ఋೞమାఋೞೞమ. ߜ௦ଶis the variance component of study subject. ߜ௦௦ଶis the 
variance component of sum sample. By literature the ICC in child ren ranges from 0.94 to 0.98. The 
variation of study subject is dominant. Fixed the study subjects, the more sub-samples taken the less 
ߜ௦௦ଶwill be by a factor 1/m. This will reduce the total variance applied in sample  size calculation. Using 
ICC=0.98, and SD=1 (Variance=1) as an example, for m=8, as an example, for m=8,  the stand deviation 
used in sample size estimation is ܦܵ=ට0.98∗1+ଵି଴.ଽ଼
଼= 0.991211 ..
The sample size calculation for this hypothesis is ba sed on the one-sample t-test for equivalence. The 
desired outcome is to reject the null hypothesis at the 0.05 significance level.  For this equivalence test of
bias, two comparisons will be performed: FloTrac vs Swan-Ganz and ClearSight vs Swan-Ganz. In order to 
preserve the overall type 1 error rate at 0.05, the Bonf erroni Correction will be used to adjust for multiple 
comparisons. 
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 22of 52 CONFIDENTIAL
Assuming a true mean bias of 0.0 and a SD of 1.0 l/mi n in the cardiac output, the sample size required for 
δ=0.5, alpha=0.05, and power=90% to reject the null hy pothesis is 45, ignoring the ICC. After considering 
ICC for eight repeated measures (m=8), a sample size of 54 Subjects in needed. After considering a 34.5% 
rejection rate for hemodynamic instability, 10% lost  to follow-up rate and 6 Roll-in Subjects for the 
learning curve, a total of 102 (96 evaluable Pivo tal Subjects and 6 Roll-in Subjects) will be enrolled.
Adjusting for multiple comparisons, considering there  will be two target devices and a reference device 
pairs, simultaneously, 108 total Subjects will be enrolled in this study.
Sample size consideration for percent error
The Critchley and Critchley method of percent error (PE) calculation will be compared to 30%. The 
Precision will be considered as acceptable if PE is less than 30 %. 
The hypothesis for PE is a one-sided test: 
H0: PE > 30%
H1: PE ≤ 30% 
The sample size calculation for this hypothesis was based on the one-sided T-test. The desired outcome is 
to reject the null hypothesis at the 0.05 significance level. Assuming a true mean of 30% and a conservative 
SD assumption of 70%, the sample size required fo r power=90% to reject the null hypothesis is 49. 
Because the study is designed with sub samples (repeat ed measurements) or sub sample sections (m= 8), 
ICC is a factor needing to be considered in the sa mple size estimation.  When eight repeated measures
(m=8) are performed, the SD=69.38%.  The corresponding sample size necessary is 49.
For PE, a sample size of n=60 will be used in the study design, after considering two pairwise 
comparisons between 2 devices with a reference device. In addition, after considering a 34.5% rejection 
rate for hemodynamic instability, 10% lost to follow-u p rate, 102 evaluable subjects will be targeted.  To 
account for the learning curve and 6 additional Roll -in Subjects will be enrolled, totaling 108 Subjects 
enrolled in the study.
Calculation of Cardiac Index (CI)
Adjusting cardiac output (CO) with study subject bo dy surface area (BSA) results in the derivation of 
cardiac index (CI). This adjustment for body surfac e area, in the study pediatric population (12 to 18 years 
old), will result in a smaller bias and percent error between test device and reference device. The standard 
deviation estimate will also be smaller, at the same sc ale, thus, the sample size estimate decreases.  
Sample size estimates for bias and perc ent error for CI is detailed in the SAP.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 23of 52 CONFIDENTIAL
Primary Safety Endpoint
The primary safety endpoint is to assess all seriou s intraoperative and post-operative adverse events 
through 30 days, including serious device-related events.
Analysis Populations
All enrolled subjects with evaluable data will be incl uded in the analysis of effectiveness endpoint, and all 
enrolled subjects will be included in the analysis of safety endpoint.
  The analysis set is composed of all evaluable subjects with valid CO matched pair measurements from the 
target medical device system (FloTrac and ClearSight systems) and the reference medical device system (the
Swan-Ganz thermodilution pulmonary artery catheter).  
Evaluable subjects are those with non-rejected interm ittent thermodilutions who have completed the 30-
day telephone follow up period.
Analysis Methods
The primary effectiveness endpoints will be accessed us ing the testing method described in the Sample Size 
Justification section. Additionally, descriptive statisti cs will be used to summar ize data. Mean, SD, median, 
25th(Q1) and 75th(Q3) percentiles, minimum, and maximum will  be reported for continuous variables;
frequency and percentage of subjects will be reported for categorical variables. Further details of the analysis 
method will be described in the Statist ical Analysis Plan for this study.
Secondary Effectiveness Endpoint
The secondary effectiveness endpoint is to demonstrate that monitoring of cardiac output (CO) with Swan-
Ganz, FloTrac and ClearSight is comparable, as determined by the Critchley and Critchley method of percent error.  
Additional Evaluations
The following additional evaluations will be included and considered exploratory:
xComparison analysis of CI as determined by th e Bland-Altman method of bias calculation with 
confidence intervals
xComparison analysis of CI as determined by the Critchley and Critchley method of percent error 
calculation with confidence intervals
xSubgroup analysis of primary and seco ndary endpoint by age stratification
xSubgroup analysis of primary and secondary endpoint by gender
xSubgroup analysis of primary and secondary endpoint by race
xSubgroup analysis of primary and secondary endpoint by site
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 24of 52 CONFIDENTIAL
x Comparison of cardiac output from FloTrac, Clea rSight and Swan-Ganz technologies to the Fick 
principle
xEvaluation of hemodynamic parameters that are collected by the FloTrac, ClearSight, Swan-Ganz
technologies, including:
oCardiac Output (CO)
oCardiac Index (CI)
oPulse Rate (PR)
oStroke Volume (SV)
xEvaluation of other hemodynamic parameters th at will be collected during the catherization 
procedure, as prespecified in the SAP
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 25of 52 CONFIDENTIAL
7. RECEIVING, STORAGE, AND RETURN OF DEVICES
Receipt of Device Supplies
A packing list will accompany all device shipments.  This list will include the inventoried product with receipt 
date and investigator and/or designee signature.  
Storage
The HemoSphere advanced monitoring platform and all inve stigational devices for use in this study shall be 
stored in a secure and clean area complying with th e storage instructions provided in the labeling.  
Device Accountability
The Investigator and/or delegated-study personnel shall  keep records documenting the receipt, use, return, 
and disposal of the devices.  Only the Investigator , delegated-Study Personnel and/or designee(s) (i.e., 
Assisting Clinician(s)) may use the devices.  The Invest igator will supervise the used of the device in Study 
subjects.  The Study site shall account for which system /device was used for which subject as well as for the 
return of the system/device.  
Return of DeviceThe Principal Investigator is responsible for returning the unused product back to the Sponsor.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 26of 52 CONFIDENTIAL
8. SCHEDULE OF EVENTS & PROCEDURES 
Schedule of Events
The following matrix shows the scheduled assessment s through the end of the Study (30-Day Follow Up).
The duration of individual study participation is expected to be 30 days ( ±14 days) after procedure. 
Data collection will occur during the study via the He moSphere platform and electronic case report forms
(eCRFs). The 30-day follow-up phone contact will be recorded on the applicable eCRF.
1Medical History / Subject Demographics / Surgical and Clinician Demographics can be obtained prior to procedure, either at the 
screening visit or on the day of procedure.
2Can be collected via the hospital record system anytime on the day of procedure or thereafter.Study Procedure / ExamSubject 
Screening Procedure Discharge30-Day Follow Up
(±14 Days)
Obtain Informed Consent X
Perform Inclusion / 
Exclusion EvaluationX
Obtain Medical History / 
Subject Demographics1 X
Assign Subject ID X
Enter Subject Data into 
MonitorX
Vital Signs X
Monitoring Duration X
Data download from 
MonitorX
Obtain Fluid and Vasoactive 
Medication Administration 
Record2X
Complete eCRFs X X X X
Record Adverse Events, if 
applicableXX X
Phone Contact 30-day 
follow up / Mortality 
DeterminationX
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 27of 52 CONFIDENTIAL
Intermittent Thermal Dilution Assessment(s)
Using the Swan-Ganz thermodilution pulmonary artery cath eter, two series of four (4) intermittent dilutions 
should be administered by the Investigator while in the cath lab.  The dilution  curves are analyzed and 
averaged to give one (1) CO value.  
CO measured by the ClearSight and FloTrac systems wil l be simultaneously compa red with the CO measured 
by the Swan-Ganz catheter using the thermodilution  method. There will be 2 sets of 4 measurements 
recorded over a 30-second interval, during the Swan- Ganz thermodilution bolus injection. Those 4 
measurements will be pair-matched by time in the Cl earSight and FloTrac system s. The same number of 
measurements that will be recorded during the Swan-Ganz thermodilution will be recorded for the ClearSight and FloTrac devices.  The follow ing thermodilution procedure will be used:
A 10 ml sample of iced glucose solution (5%) will be  drawn through an iced injectate container (CO-SET+ or 
any other container that meets the requirements, as determined by the investigator) and injected in a 
steady manner. Four TD CO determinations will output, preferably within 5 minutes.  From there, three values, will be averaged to obtain one single value. Ea ch thermodilution curve will be visually checked 
before acceptance. The dilution curve will be automati cally corrected for the temperature of the blood and 
of the injectate measured at the en trance of the catheter lumen. Valu es for temperatures will be stored 
together with the thermodilution values . The entire series of four thermodilution estimates will be rejected 
if, during an injection, the HemoSphere advanced mo nitor displays an alert signal, if the injectate 
temperature is above 10 °C, or when the curve of the di lution is abnormal. In case  of rejection, the entire 
series of four thermodilutions will be repeated.
Hemodynamics and respiratory rate must be stable du ring the TD series, since variability violates the 
assumption of stability that  is required for the TD technique.   Spon sor-instream review of the TD series will 
occur after each catheterization to determine if hemody namic variability occurred an d the site team will be 
retrained on the importance of conducting the TD technique during hemodynamic stability.  
Clinical Study Completion or Early Termination
The IRB will be notified upon completion or premature termination of the study. Edwards retains the right to 
suspend or prematurely terminate this clinical study at any time.
If suspicion of an unacceptable risk to subjects arises during the clinical investigation, or when so instructed 
by the IRB or regulatory authorities, Edwards shall suspend the study while the risk is assessed by the Data Safety Monitoring Board (DSMB). Edwards shall terminate the clinical investigation if an unacceptable risk is 
confirmed.
Protocol Deviation
Any deviations from the protocol will be documented on the protocol deviation eCRF. The Investigator/or 
Designee shall be responsible for the reporting of any deviations deemed reportable to the IRB.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 28of 52 CONFIDENTIAL
Deviations shall be reported to the Sponsor, regardless of  whether they are medically justifiable, pre-approved 
by the sponsor, or taken to protect the subject in an emergency. Subject-specific deviations will be reported on the appropriate eCRF.
Non-subject specific deviations (e.g. unauthorized use of a device outside the study, etc.) will be reported in 
writing. The investigator will also adhere to procedures  for reporting study and subject specific deviations to 
their IRB in accordance with their specif ic IRB’s reporting policies and procedures.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 29of 52 CONFIDENTIAL
Changes to the Protocol 
Changes to the research covered by this protocol must  be implemented by formal protocol amendment. All 
amendments to the protocol must be initiated by the Sponsor.
Protocol amendments must not be implemented with out prior IRB approval. Documentation of amendment 
approval by the Investigator and IRB or IEC must be provided to the Sponsor or its authorized representative. 
When the change(s) involve only logistic or administr ative aspects of the study, the IRB only needs to be 
notified.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 30of 52 CONFIDENTIAL
9. RISK ANALYSIS
Anticipated Risks
Edwards will monitor for safety which include those po tentially associated with use of the devices and its 
components.  There may be  additional risks and discomforts that are not known at this time.
Any events associated with a commercially available study device (Fore-Sight Elite Tissue Oximetry Sensors)
will be reported in accordance with  the Medical Device Reporting (Complaints) regulation (21 CFR Part 803), 
while events associated with the investigational devices ( remainder of devices in this study) will be reported 
under the IDE program (812.150).
Below is a list of general anticipated risks associated with the type of surgeries and procedures, which may 
be conducted as standard of care.
xRisks related to transplantation of donor organ:
oDeath
oExplant of donor organ
oHemorrhage
oOrgan transplant failure
oRespiratory Failure
oSepsis/Infection
xRisks related to other surgical or patient factors:
o30-day mortality
oCardiac arrest
oCardiac arrhythmia
oHemorrhage
oIleus
oNausea and vomiting
oPneumonia
oProlonged Hospital length of stay
oProlonged ICU length of stay
oPulmonary embolism
oSepsis
oTransfusion need
oWound infection
Below is a list of anticipated risks that may be associated with the use of Swan-Ganz thermodilution 
pulmonary artery catheter:
xAllergic reaction to latex
xCardiac arrhythmias
xComplete heart block
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 31of 52 CONFIDENTIAL
xKno tting
xNitroglycerin absorption
xPerforation of th e pulmonary artery
xPneumothorax
xPulmonary infarction
xThrombocytopenia
xThrombophlebitis
xThrombosis
xTricuspid and pulmonic valve damage
xRight bundle branch block
xSepsis/Infection
Below is a list of anticipated risks that may be associated with the use of the FloTrac Sensor:
The vascular access obtained is standard clinical care for the adult population and th e addition of the FloTrac 
sensor is and is not expected to impose any additional ri sk to the patient. There is no measurable increased 
infectious risk with the temporary use of the FloTrac sensor.
Below is a list of anticipated risks that may be asso ciated with the use of the ClearSight finger cuff:
xDiscoloration of digit distal to the cuff
xDiscomfort where the cuff is applied
xPain associated with inflation of the cuff
xSlight numbness of the fingertip
Below is a list of anticipated risks that may be as sociated with the use of ForeSight Elite Sensors:
xAllergic reaction to adhesive on sensors
xSkin irritation
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 32of 52 CONFIDENTIAL
Risk Management 
The study devices have been tested to an established regimen of safety and performance testing and, with 
the exception of the ClearSight Module used in the He moSphere platform, have been cleared by the US FDA
in adults.  The ClearSight technology has been cleared for use in adults with the EV1000 Monitor; however, it has not been cleared for use with the He moSphere advanced monitoring platform. 
The current risks identified for using these products do not outweigh the benefit the patient will receive.   
Furthermore, this study is: 
1) Being conducted on patients who are already planne d to receive an arterial line and a Swan Ganz 
catheter and the addition of FloTrac and ClearSight  do not add to the invasiveness of the study,
2) Being conducted on patients who are al ready planned to receive thermodilutions 
3) An observational study as oppose d to an interventional study
4) Not relying on the data obtained from th e FloTrac and ClearSight to treat patients
Collecting data does not introduce any new risks in relation to these products. Regarding the ClearSight 
Module used in the HemoSphere platform, thorough test ing has been performed to show that this system 
functions as intended. As such collectively , the risks do not outweigh the benefits.
  
BenefitsThere are no guaranteed benefits from a subject’s partic ipation in this study.  However, the ForeSight Elite 
Sensors are cleared for pediatric use and provide the benefit of continually monitoring oxygen saturation of tissue with accuracy and precision.  When desatu ration of tissue occurs , the following may occur:
xCognitive disfunction
xExtended time on mechanical ventilation
xExtra days spent in the hospital or intensive care unit (ICU)
xIncreased post-operative nausea and vomiting
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 33of 52 CONFIDENTIAL
10. REPORTABLE EVENTS
Recording and Reporting of Adverse Events
The Investigator and/or Designee(s) will determine wh ether any adverse events (AEs) have occurred.  An 
AE is defined as any untoward medica l occurrence in a clinical Study of an Investigational Device regardless 
of the causal relationship of the problem with the device or, if applicable, other Study treatment or 
diagnostic product(s).  Information for AEs with the study devices will be collected from the time a subject 
begins the study procedure and is ex posed to Study products.  AEs will also be collected during surgical 
intervention, post intervention, discharge and through the 30-day follow-up.  AEs may be volunteered by 
subjects, clinicians, elicited from questioning by Investigator and/or Designee(s), or collected via 
observation.  When a device or study related AE is suspected all available event information and will be 
provided to the Clinical Events Committee. 
Once an AE/SAE/UADE is confirmed as such, event, date of onset, severity, duration, treatment (if 
required), resolution (or ongoing), assessment of seriousness, relationship to Study procedure and 
relationship to device will be recorded on the approp riate eCRF or SAE Report Form and submitted as 
necessary by the Investigator and/or Designee(s).  An y suspected AEs related to the Investigational Device 
or Study procedure must be reported to the Sponsor or designee within 5 working days of first awareness 
of the event.  
Recording and Reporting of Adverse Device Effects
An adverse device effect (ADE) is defined as an AE re lated to the use of an investigational medical device.  
This definition includes AEs resulting from insufficien t or inadequate instructions for use, deployment, 
implantation, installation or operation, or any malfuncti on of the investigation de vice.  It also includes any 
AE resulting from use error or from intentio nal misuse of the Investigational Device.  
Causality of relationship to the Investigational De vice will be judged by the Investigator, and reviewed
independently by the Clinical Events Committee, as follows:Not related: 
xAn event is clearly not and cannot be related to  the Investigational Device.  Reporting is not 
required per protocol unless the event was rela ted to the Investigational Device or Study.
Possibly Related:
xA relationship may exist but could have been pr oduced by another cause (e.g., treatment, 
condition).
Related:
xA relationship can be directly attributed to the use of the Investigational Device.
ADEs must be reported to the Sponsor or designee, wi thin 24 hours of first awareness of the event.  
Notification should be done via email, fax, telephon e or direct communication followed by direct entry of 
AE/SAE data into the eCRF.  In addition, the Study site will report confirmed ADEs related to their IRB in 
accordance with the IRB’s requirements.  ADEs w ill also be reported to the FDA, as required.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 34of 52 CONFIDENTIAL
Recording and Reporting of Serious Adverse Event
A serious adverse event (SAE) is defined as an AE th at results in any of the following outcomes: death, a 
life-threatening adverse event, inpatient hospitalizat ion or prolongation of ex isting hospitalization, a 
persistent or significant disability/incapac ity, or a congenital anomaly/birth defect.
Recording and Reporting of Serious Adverse Device Effects
A serious adverse device effect (SADE) is an AD E that has resulted in any of the consequences or 
characteristics of a SAE.  
SADEs must be reported to the Sponsor or designee, within 24 hours of first awareness of the event.  
Notification should be done via email, fax, telephon e or direct communication followed by direct entry of 
AE/SAE data into the eCRF.  In ad dition, the Study site will report confirmed SADEs their IRB in accordance 
with the IRB’s requirements.  SADEs will al so be reported to the FDA, as required.
Recording and Reporting of Unan ticipated Adverse Device Events
Unanticipated adverse device effect (UADE) is define d in 21 CFR 812 as any serious adverse effect on 
health or safety or any life-threatening problem or de ath caused by, or associated with, a device, if that 
effect, problem, or death was not previously identified  in nature, severity, or degree of incidence in the 
investigational plan or application (including su pplementary plan or application), or any other 
unanticipated serious problem associated with a device  that relates to the rights, safety, or welfare of 
subjects. In contrast, an anticipated adverse device ef fect is an effect which by its nature, incidence, 
severity, or outcome has been identi fied in the risk analysis report.
UADEs must be reported to the Spon sor or designee within 24 hours and submitted to the reviewing IRB as 
soon as possible, but in no event later than 10 working days after the Investigator first learns of the effect.
All AEs related to the Investigational Device or St udy will be reviewed by the Investigator and/or 
Designee(s) and Sponsor.  These AEs will be followed until they are adequately resolved, explained by the 
Investigator and/or Designee(s), un til subject has completed follow-up or been withdrawn from the Study.  
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 35of 52 CONFIDENTIAL
Recording and Reporting of Deaths
Events resulting in death during the subject’s enrollment  in this Study are not expected to occur as a result 
of participation in the Study.  In the event of subjec t death; however, every reasonable effort should be 
made to obtain a copy of the autopsy report and/or de ath summary.  Information on the date and cause of 
death and its relationship to the Study device will be  determined by the Investigator and/or Designee and 
recorded on the appropriate AE eCRF and submitted on an SAE Report Form as necessary.
Recording and Reporting of Adverse Events Associated with Commercial Components
Any adverse event associated with an FDA cleared comp onent will be recorded as a device complaint and 
reported via the MDR program (21 CFR Part 803).  Co mplaints will also be reported to the IRB in 
accordance with each IRB’s requirements.  Device comp laints should be reported to the Sponsor as soon as 
the site becomes aware of the complaint.
Recording and Reporting of Pre-Existing Conditions
Pre-existing medical conditions and symptoms due to pre-existing medical conditions, surgery or admission to ICU will not be recorded as adverse even ts. The admission of a critically ill patient in the 
intensive care unit is commonly due to one or severa l serious medical conditions and/or a major surgery, 
which may cause changes and abnormalities of blood ch emistry, diagnostic and physiological parameters.  
In the event there is a deterioration of a pre-existing  medical condition or symptoms due to the use of the 
Study products or a Study related procedure, then the re view of the event will be initiated, and an AE will 
be recorded if it meets the definition.  Any events oc curring prior to the study procedure will be recorded 
as medical history. 
Reporting Adverse Events to the FDA
Confirmed UADEs will be evaluated by the Clinical Events  Committee.  The FDA, all participating principal 
investigators and their reviewing IRBs will be informed no later than 10 working days after Edwards Lifesciences or designee first becomes aware of the effect.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 36of 52 CONFIDENTIAL
Reporting Adverse Events to the Responsible IRB
In accordance with applicable policies of the IRB, th e Investigator will report, any observed or volunteered 
confirmed adverse event that is determined to be (1 ) unexpected; (2) related or possibly related to the 
research; and/or (3) involves increased or greater ri sk of harm to participant(s) or others than was 
previously known or approved by the IRB.  AE report s will be submitted to the IRB in accordance with the 
IRB policies and procedures.
Confirmed UADEs will be evaluated and the reviewing IRB will be informed of the results of the Study no 
later than 10 working days after Edwards or when  the designee first becomes aware of the effect.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 37of 52 CONFIDENTIAL
11. INDEPENDENT SAFETY COMMITTEES 
Clinical Events Committee
An independent (3-Member) Clinical Events Committee (CEC) will be established to oversee the safety 
progress. Members of the CEC must be free of signific ant conflicts of interest (e.g. Financial, intellectual, 
professional, or regulatory), and are experts in all sc ientific disciplines needed to interpret the data and 
ensure study participant safety. The CEC will meet via teleconference a minimum of two (2) times over the 
course of the study. The CEC may also meet for an  ad hoc review of data in the event that a UADE is 
reported. The CEC charter will be maintained by the Spon sor as part of the clinical study project plan. The 
CEC charter will outline membership and voting proc edures as well as CEC Meeting documentation and 
communication.
The CEC will perform the following activities:
xAdjudicate all adverse events based on whether the events were:
oSerious/Non-Serious
oAnticipated/Unanticipated
oRelated to procedure and/or device
x
The CEC will convene to provide an immediate adjudication [within 48 hours] of unanticipated adverse device effects [UADE] in terms of anticipation, severity and relatedness to study devices.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 38of 52 CONFIDENTIAL
Data Safety Monitoring Board
An independent (4-Member) Data Safety Monitoring Bo ard (DSMB) will be established to oversee the Study 
outcome. Members of the DSMB must be free of signific ant conflicts of interest (e.g. Financial, intellectual, 
professional, or regulatory) and are experts in all scie ntific disciplines needed to interpret the data and 
ensure study participant safety, including an inde pendent biostatistician. The DSMB will meet via 
teleconference a minimum of one (1) time over the cour se of the study. The DSMB manual of operation 
(MOP) will be maintained by the Sponsor as part of the clinical study project plan. The DSMB MOP will 
outline membership and voting proc edures as well as DSMB Meeting documentation and communication.  
The DSMB meetings will include an open session whe re the Sponsor will present study updates, review 
trends for device malfunctions, protocol deviations and subject withdrawal reasons to communicate study 
progress.  The Investigators may attend the open session.  
In addition to the open portion of the DSMB meetin gs, there will be closed sessions that will only be
attended by the DSMB members.
The DSMB will perform the following activiti es during the closed session of the meetings:
xAssess primary safety endpoint 
xAssess participant risk versus benefit, performanc e of study sites, and other factors that can affect 
study safety outcome
xReview factors external to the study when interpre ting the data, such as scientific or therapeutic 
developments that may have an impact on the safety  of the participants or the ethics of the study
xMake recommendations to Edwards Lifesciences, IRB, and investigators concerning continuation 
or conclusion of the study based  solely on safety evaluation
xProtect the confidentiality of the study data and the results of monitoring
To mitigate any potential release of study results, the analysis of safety endpoint will be led by the 
independent biostatistician serving on the DSMB.  The bi ostatistician will have no contact with the Sponsor 
or any study sites.  Furthermore, the identification of the other DSMB members will not be shared with the 
sites during the conduct of the study.  
Stopping Rules
Continuation or discontinuation of the study will be based upon the DS MB’s evaluation of study safety.  
The DSMB may recommend stopping the study based solely on any safety concerns. 
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 39of 52 CONFIDENTIAL
12. DATA HANDLING AND RECORD KEEPING
Confidentiality 
Information about Study subjects will be kept confiden tial and managed according to the requirements of 
the Health Insurance Portability and Accountability Act of  1996 (HIPAA).  Consistent with these regulations, 
a signed authorization will be obtained that  informs each subject of the following:
xWhat protected health information (PHI) will be collected from subjects in this Study 
xWho will have access to that information and why
xWho will use or disclose that information
xThe rights of a research subject to revoke  their authorization for use of their PHI 
No subject demographic data or medical information w ill be used or shared outside the Sponsor and site 
staff unless an unanticipated adverse de vice effect (UADE) is reported. If a UADE is reported, all efforts will 
be made to keep subject information confidenti al. The Sponsor is dedicated to maintaining the 
confidentiality and privacy of subjects who volunteer to  participate in the Study.  The Study Investigator and 
the Study site personnel are responsible for maintaini ng confidentiality throughout the clinical Study. The 
Sponsor and Sponsor designated Study personnel will have access to the data collected.  The hard copies of 
the source documentation are to be maintained in a secure area with limited access.
To protect subject confidentiality, the subject’s name must not appear anywhere on CRFs, or supporting 
documentation removed from the site.  All subject id entifiers (e.g., social security number) will be 
obliterated from all photocopies of source document s that have been removed from the site.  All Study 
documents will identify the subject by a subject Study identification number and Protocol number assigned 
by the Sponsor (if applicable).
In the event that a subject revokes auth orization to collect or use PHI, the Investigator, by regulation, retains 
the ability to use all information collected prior to the revocation of subject authoriz ation.  For subjects that 
have revoked authorization to collect or use PHI, attempt s should be made to obtain permission to collect at 
least vital status (i.e. that the subject is al ive) at the end of their scheduled Study period.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 40of 52 CONFIDENTIAL
Source Documents
Source data are all information, original records of clinical findings, observations, or other activities in a 
study necessary for the reconstruction and evaluation of the study.  Source data are contained in source 
documents.  Examples of these original documents, and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfic hes, photographic negatives, micr ofilm or magnetic media, x-rays, 
subject files, source worksheets that have been certifie d as source, and records kept  at the pharmacy, at the 
laboratories, and at medical-technica l departments involved in the study.
Required data for this Study are to be recorded in the subject’s file and/or in worksheets, certified as source, 
for source documentation and data verification unless otherwise specified.  Protocol deviation information 
can be recorded directly on the Protocol Deviation eCRF.  Some of the source documentation generated 
during the Study may be either a worksheet, the electr onic data from the Monitor, laboratory data, or 
printout from Radiometer and YSI.  It is recommend ed that electronic case report forms (eCRFs) be 
completed within 24 hours of data availability, but not more than 10 working days after completion of 
assessments. Because of the potential for errors, inaccuracies, and illegibility in transcribing data onto 
eCRFs, the Investigator must permit inspection of the source documents.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 41of 52 CONFIDENTIAL
13. DATA COLLECTION METHODS
Study data will be captured utilizing electronic Case Report Forms (eCRFs) including the 30-day follow-up call
as well as downloaded files captured directly via the use of the HemoSphere advanced monitor. Data collected 
from the HemoSphere advanced monitor will be do wnloaded at the end of each catheterization procedure
and stored on a USB stick. USBs will be stored in a secure  location at the site, accessible only to Study site 
personnel. The HemoSphere data on USBs may be shippe d to the Sponsor at any point in time of the study
per the request of the Sponsor.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 42of 52 CONFIDENTIAL
14. RECORD RETENTION 
It is the Investigator’s responsibility to retain Study essential documents during the investigation and for a 
minimum period of two (2) years after the investigation is terminated or co mpleted, or the records are no longer 
required for the purposes of supporting a premarket approval  application or a notice of completion of a product 
development protocol.  These documents should be retained  for a longer period if required by an agreement with 
the Sponsor. In such an instance, it is the responsibility of the Sponsor to inform the Investigator/institution as to 
when these documents no longer need to be retained.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 43of 52 CONFIDENTIAL
15. STUDY DOCUMENTATION 
Study Records 
Edwards will maintain accurate, complete, and current records relating to the conduct of the study.
Records to be maintained by Edwards Lifesciences and the study site include but are not limited to:
xStudy protocol and all amendments, if applicable
xIRB approved Informed Consent
xIRB approval letter, including informed consent form
xIRB membership list, or alternative notification of IRB being duly constituted or Department of Health 
and Human Services Multiple Projects Assurance Number
xIRB correspondences
xStudy training logs
xDevice accountability records 
xRequired reports, if applicable
The following records must be maintained for each subject enrolled in the study:
xSigned informed consent form
xAll completed eCRFs
xSupporting documentation of any adverse events
Study Reports
Designated site personnel shall prepare and submit the following accurate and complete reports in a timely 
manner to the IRB and FDA, if applicable:
xReport of an Unanticipated Adverse Device Effects (U ADEs) as soon as possible, but in no event later 
than 10 working days after the first awareness of the event. After an internal evaluation, Edwards shall 
report the results of such evaluation to FDA and to  all reviewing IRBs and participating investigators 
within 10 working days after receipt of notice of the effect. 
xWithdrawal of IRB approval within 5 working days to Edwards. Thereafter, Edwards shall notify FDA 
and all reviewing IRBs and participating investigators of any withdrawal of appr oval of an investigation 
or a part of an investigation by a reviewing IRB within 5 working days after receipt of the notification 
of withdrawal of approval.
xProgress reports will be submitted to th e IRB as required and no less than yearly.
xDeviation from the study protocol to protect the subject’s life or physical well-being in an emergency 
will be reported to Edwards as soon as possible, but in no event later than 5 working days after the 
emergency occurred. Non-emergency deviations will  be reported to the IRB, as required. If deviations 
may affect the scientific soundness of the plan or th e rights, safety, or welfare of human subjects, FDA 
and IRB shall be notified.
xA final written report is submitted to the IRB within  6 months after completion or termination of the 
study as required.
xUpon request by the reviewing IRB or FDA, Edwa rds will provide accurate, complete, and current 
information about any aspect of the investigation.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 44of 52 CONFIDENTIAL
xUse of the study device without informed consent will be reported to Edwards and the IRB within 5 
working days after the use occurs. Thereafter, Edwards shall notify FDA within 5 days of receipt of notice.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 45of 52 CONFIDENTIAL
Communication Procedures
Edwards will utilize an electronic regulatory binder to maintain required study documentation including 
applicable correspondences during the course of the study. 
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 46of 52 CONFIDENTIAL
16. STUDY MONITORING, AUDITING AND INSPECTING 
Site Selection
The Study site(s) for this Study will be pre-screened by  the Sponsor.  The Principal Investigator will be 
selected based on their training and experience with this type of research activity and available subject 
population.  The Sponsor will provid e the Investigator with informati on, Study specific training, and 
supplies necessary to conduct the Study.
Study Monitoring Plan
A Monitoring Plan will be created to address moni toring arrangements and the extent of source data 
verification.  A Study monitor will be assigned to monitor the progress of the Study by the Sponsor.  The 
Study monitor may be either an employee of the Sp onsor or contracted.  The Study monitor will be 
responsible for reviewing eCRFs and monitoring the Study site routinely to observe Study progress and 
compliance with Study Protocol.  The Investigator must permit inspection of the source documents, 
regulatory binders and other Study related documents provided by the Sponsor.  
Study monitoring visits will be sc heduled throughout the duration of the Study between the Study monitor 
and the Investigator and/or Designee at a mutually convenient and available time.  These visits will assure 
that the facilities are still acceptable, the Protocol an d investigational plan are being followed, the IRB has 
been notified of approved Protocol changes as required, complete records are being maintained, 
appropriate timely reports have been made to the Sponsor and the IRB, device and device inventory are 
secure and the Investigator is carryi ng out all agreed activities.  Any personnel changes must be reported 
to the Study monitor immediately.  
All eCRFs will be maintained in a validated EDC system and missing or unclear data will be queried as 
necessary throughout the Study.  The Sponsor may request further information and documentation when 
complications and/or malfunctions are observed and reported.
Interim Monitoring Activities 
The Sponsor has the obligation to monitor the conduct of this study to ensure that the study is conducted 
in accordance with the protocol, Edwards Lifesciences procedures and 21 CFR 812.46 Monitoring Investigations.  
Interim monitoring visits (onsite or remote) will be conduc ted to evaluate the progress of the study, verify 
the rights, well-being, and protection of the patients, and verify that the reported clinical study data is 
accurate, complete and verifiable fr om the electronic medical records an d source documents.  Monitoring 
visits will be made in accordance with the Monitoring Plan.   
Site Close-Out Visit
The Investigator will be notified in writing upon te rmination or completion of  the Study.  The Sponsor 
retains the right to suspend or prematurely terminat e this clinical investigati on at any time.  Upon 
completion or premature termination  of the Study, the Study monitor will perform a close-out visit.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 47of 52 CONFIDENTIAL
A site will be considered closed when the following criteria are met:
xLast subject completes 30-day follow-up
xAll data queries are resolved
xA site closeout visit is completed
xThe IRB is notified in writing of site and st udy closure in accordance with their requirements
Auditing and Inspecting 
In the event that audits are initiate d by the Sponsor or national/intern ational regulatory authorities, the 
Investigator shall allow access to the original medi cal records and provide all requested information, as 
applicable.  The Investigator will permit Study-related  monitoring, audits, and inspections by the Research 
Quality Assurance Office, IRB, the Sponsor, and go vernment regulatory bodies, of all Study related 
documents (e.g. source documents, regulatory document s, data collection instruments, Study data etc.).  
The Investigator will ensure the capability for insp ections of applicable Study-related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.).
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 48of 52 CONFIDENTIAL
17. ETHICS
Ethical and Scientific Conduct of the Clinical Research Study 
The Study may only commence once IRB approval and regulatory approval, as  applicable, are received.  This 
Study will be conducted in compliance with the Pr otocol approved by the IRB, the relevant federal 
regulations, and IRB policies and procedures and according to Good Clinical Practice standards.
The Investigator shall ensure that all work and services described herein, or incidental to those described 
herein, shall be conducted in accordance with the highes t standards of medical and clinical research practice 
and the applicable regulations.  The Investigator will provide copies of the current Study Protocol to all Study 
site personnel responsible for Study conduct.
As the Sponsor of this clinical Study, Edwards Lifesciences has the overall responsibility for the conduct of 
the Study, including assurance that the Study meets the regulatory requirements of the pertinent regulatory 
agencies.  Edwards Lifesciences will also ensure compli ance with the signed clinical agreement, the Protocol, 
the requirements of applicable regulations, and any conditions of Study approval by the IRB.
The Sponsor may transfer study related duties and functi ons to a CRO.  Transferred duties and functions will 
be specified in a written agreement.  Ultimate responsi bility for the quality and integrity of the Study resides 
with the Sponsor.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 49of 52 CONFIDENTIAL
18. FINANCIAL DISCLOSURES
Appropriate financial disclosures will be obtained from  all Principal Investigator s and Sub-Investigators and 
additional personnel listed on the St atement of the Investigator.  The Investigator will provide sufficient and 
accurate financial disclosure information to the Sponsor.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 50of 52 CONFIDENTIAL
19. PUBLICATIONS 
At the conclusion of the Study, a manuscript may be prepa red for publication in a scientific journal.  The Sponsor 
reserves the right to review any manuscripts prior to submi ssion.  The Study will be entered into a clinical trial 
registry databank such as clinicaltrials.gov.
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 51of 52 CONFIDENTIAL
20. ACRONYMS AND ABBREVIATIONS
Acronym Entire Word
ADE Adverse Device Effect
AE Adverse Event
ASA American Society of Anesthesiologists
BP Blood Pressure
CI Cardiac Index
CCO Continuous Cardiac Output
CO Cardiac Output
CEC Clinical Events Committee
CRF Case Report Form
DSMB Data Safety Monitoring Board
FDA Food and Drug Administration
eCRF Electronic Case Report Form
EDC Electronic Data Capture
GCP or gCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
HR Heart Rate
Hr Hour
ICC Intra-Cluster Correlation
ICF Informed Consent Form
ICO Intermittent Cardiac Output
ICU Intensive Care Unit
IRB Institutional Review Board
ITT Intent-to-Treat
mL Milliliters 
mITT Modified Intent-to-Treat
N Total Sample Size
NCT National Clinical Trial
PAC Pulmonary Artery Catheters
PI Principal Investigator 
PR Pulse Rate
SADE Serious Adverse Device Effect
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SpO2 Peripheral Capillary Oxygen Saturation
Sub-I Sub-Investigator 
SV Stroke Volume
SVI Stroke Volume Index
SVV Stroke Volume Variation
SVR Systemic Vascular Resistance
UADE Unanticipated Adverse Device Effect
     
POGO Study
Study #2019-08
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC.  IT MAY NOT BE REPRODUCED OR 
DISCLOSED WITHOUT PRIOR WRITTEN PERMISSION FROM EDWARDS LIFESCIENCES, LLC.Edwards Lifesciences, Edwards, the stylized E logo, HemoSphere, Swan-Ganz, FloTrac, ClearSight and ForeSight Elite are trademarks  of Edwards 
Lifesciences Corporation.
2019-08 Page 52of 52 CONFIDENTIAL
21. REFERENCES
1. Richard C, Monnet X, and Teboul JL. Pulmonary art ery catheter monitoring in 2011. Current opinion in 
critical care 2011; 17: 296-302.
2. Swan HJ, et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. 
The New England journal of medicine 1970; 283: 447-451.
3. Mehta Y, and Arora D. Newer methods of cardiac ou tput monitoring. World journal of cardiology 2014;
6: 1022-1029.
4. Sigurdsson, TS., et al. Extracorporeal arteriovenous ultrasound me asurement of cardiac output in small 
children. Anesthesiology 2019; 130:712-8.
5. Blalock A.  Mechanism and trea tment of experimental shock: Shock following hemorrhage. Arch Surg
1927; 15:762–98.
6. Guyton AH and Hall JE. Overview of  the circulation: Medical physics of  pressure, flow, and resistance. In 
Textbook of Medical Physiology , 11th edition, Edited by S. Elsevier, Elsevier, Inc., Philadelphia, pp 161–
170
7. Trieu,  C, et al.   Babies and children at last - Pediatric ca rdiac output monitoring in the twenty-first 
century. Anesthesiology 2019; 130:712.
8. Suehiro K, et al. Accuracy and precision of minimally-invasive  cardiac output monitoring in children: a 
systematic review and meta-analysis. J Clin Monit Comput 2016; 30:603–620.
9. Argueta, E and Paniagua, D. Thermodilution card iac output: A concept over 250 years in the making. 
Cardiology in Review 2019; 27: 138-144.
10. Martina, JR, et al . Noninvasive continuous arterial bloo d pressure monitoring with Nexfin®. 
Anesthesiology 2012; 116:1092-103.
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISCLOSED TO THIRD PARTIES WITHOUT  
PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC.  DOC -0089208 Rev A (This Template is required by DOC -0089206)   
  
Revision Date: December 2, 2020   
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 1 
Title Statistical Analysis Plan for A Prospective, Single- Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
  
 
 
 
 
STATISTICAL ANALYSIS PLAN  
 
  
 
Protocol Title:  A Prospective, Single- Arm, Nonrandomized, Observational Study  of 
Cardiac Output Monitoring in Pediatric Patients  
Protocol Number:  #2019 -08 
SAP Version:  B 
SAP Date:  December 2, 2020  
SAP Author:   
  
 
 
  
 
 
CONFIDENTIAL  

THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO THIRD PARTIES WITHOUT 
PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. DOC-0089208 Rev A (This Template is required by DOC-0089206)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 3 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
  
 
TABLE OF CONTENTS 
 
 
1. INTRODUCTION 5 
2. STUDY DESIGN 5 
2.1 Study Objectives 5 
2.2 Overall Study Design and Plan 5 
2.3 Sample Size Consideration 7 
3. STUDY ENDPOINTS 12 
3.1 Primary effectiveness endpoint 12 
3.2 Secondary effectiveness endpoints 13 
3.3 Explatory analyses 13 
3.4 Explatory analyses 14 
4. ANALYSIS POPULATIONS 15  
5. DEFINITIONS 15 
6. DATA AND ANALYSIS CONVENTIONS 16  
6.1 General Conventions 16 
6.2 Handling of Missing 16 
6.3 Handling of Invalid Data 16 
7. SUMMARY OF BASELINE INFORMATION 17 
7.2 Demographics and Baseline Characteristics 18 
7.3 Medical History 18 
8.  STATISTICAL ANALYSIS OF STUDY ENDPOINTS 21 
8.1 Primary Endpoint 21 
8.1.1 Summary statistics and statistical comparison  21 
8.1.2 Primary endpoint analysis with Bias calculated by CO  21 
8.1.3Limits of Agreement  Error! Bookmark not defined.  
8.2 Secondary Endpoint 22 
8.3 Sensitivity Analysis 22 
8.4 Exploratory Analyses 22 
8.5 Interim analysis 23 
8.6 Analysis of other hemodynamic parameters 23 
9. ANALYSIS OF SAFETY 25 
9.1 Deaths 25 
9.2 Adverse Events Error! Bookmark not defined.  
11. REFERENCES 26 
12. APPENDIX 27 
13. LITERATURE SEARCH/REVIEW 27 
14. PEER REVIEW REQUEST, PER SAP INSTRUCTION (DOC-0089205) 28 
 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISCLOSED TO THIRD PARTIES WITHOUT  
PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC.  DOC -0089208 Rev A (This Template is required by DOC -0089206)   
  
Revision Date: December 2, 2020   
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 4 
Title Statistical Analysis Plan for A Prospective, Single- Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
  
 
Glossary of Terms  
 
 
ABBREVIATION  DEFINITION OR DESCRIPTION  
  ABP  Arterial Blood Pressure  
  AE Adverse Event  
  ADE Adverse Device Effect  
  Alpha  Type I error in hypothesis test  
  Beta  Type II error in hypothesis test  
  BSA  Body Surface Area  
  CEC  Clinical Events Committee  
  CI Cardiac Index  
  CI Confidence Intervals  
  CO Cardiac Output  
  CSR  Clinical study report  
  eCRF  Electronic Case Report Form  
  GCP  Good Clinical Practice  
  H0 Null hypothesis  
  H1 Alternative hypothesis  
  MAP  Mean Arterial Pressure  
  ICC Intra-cluster correlation coefficient  
  IRB Institutional Review Board 
  PAC Pulmonary Artery Catheter  
  PE Percent Error  
  SAE  Serious Adverse Event  
  SAP Statistical Analysis Plan  
  SD Standard Deviation 
  SV Stroke Volume  
  TD Thermodilution  
 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DI SCLOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC.  
DOC -0089208 Rev. A (T his template is required by DOC -0089205)   
  
Revision Date: December 2, 2020   
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 5 
Title Statistical Analysis Plan for A Prospective, Single- Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
 
1. INTRODUCTION 
 
This statistical analysis plan (SAP) specifies the statistical methods to be implemented for the analysis of data 
collected within the scope of Edwards Lifesciences’s Protocol #2019 -08, “A Prospective, Single -Arm, 
Nonrandomized, Observational Study  of Cardiac Output Monitoring in Pediatric Patients ”, and provides 
detailed instructions as to how each analysis will be performed.  
 
Results obtained from the analyses specified in the SAP will become the basis of the clinical study report (CSR) 
for this protocol.  Any deviations from the SAP must be documented in the CSR.  
 
2. STUDY  DESIGN  
 
2.1 Study  Objectives  
 The primary objective of the study is to assess Cardiac Output Monitoring in pediatric subjects by comparing 
FloTrac ™ and ClearSight ™ to intermittent thermodilution Swan -Ganz™ , in order to expand the indications of  
FloTrac ™, ClearSight ™ and Swan- Ganz Intermittent  Thermodilution Catheter to the pediatric popula tion 12 to 
18 years of age .  
 
2.2 Overall Study Design and Pl an 
 
This is an observational study in the U.S.  A subject will be considered enrolled in the study once the subject has 
signed the informed consent, a Swan -Ganz catheter has been deployed, a FloTrac has been connected, a 
ClearSight finger cuff has been attache d and ForeSight Elite sensors have been placed.  The Study ID will be a 6 -
digit number, the first three numbers will identify the site, and the second set of numbers will identify the subject identification number. Subjects will be enrolled in age group, 12 to 18 years of age.  
 
A Swan- Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed prior 
to the start of the surgery.  There will be 2 sets of 4 intermittent cardiac output measurements recorded, each over a  30 second interval during the bolus injection . Measures for FloTrac and ClearSight will be retrospectively 
matched by time point to the Swan -Ganz catherization data.  Intermittent cardiac output and other 
hemodynamic parameters will be collected throughout  the duration of the surgery.  For each study subject two 
sets of four repeated measurements will be taken in the cardiac catherization lab.  Data collected in this study will support in expanding the current indications of Swan -Ganz, FloTrac and ClearSight into the pediatric 
population.  
 In order to avoid a learning curve bias, up to 6 roll- in subjects will be enrolled, which is counted in the final 
sample size in study.  The collected data from the roll- in cohort will be analyzed separately from the pivotal 
study subjects.  
   
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 6 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
A modified intent-to-treat (mITT) principle will be app lied. Through investigator professional judgement and 
statistical principles, this study will be conducted in a manner that is consistent with the applicable regulations 
and in accordance with current Good Clinical Practice (GCP). 
 
All methods of measurements will be recorded for all devi ces and included as part of  the data set. Edwards will 
conduct analyses both with and without observations that are determined to be outliers.  Once outliers are identified, the Principal Investigator will assess the validity of the data.   
 
2.2.1 Cardiac Output  
Cardiac output will be continuously  measured by FloTrac and ClearSight, while cardiac output will be 
intermittently measured by the Swan-Ganz catheter, using the thermodilution method.  During a 5- minute 
period of thermodilution and cardiac output determination, each subject will be assessed for hemodynamic stability. Should there be any instability, the bolus will be rejected. All data will be recorded and any rejected 
values will be clearly identified in the eCRF.  
 The rejection criteria that will be used to de termine hemodynamic instability are detailed below: 
   
x FloTrac and ClearSight will display mean arterial pr essure (MAP).  If MAP varies  > 15% during the 
30-sec period of each intermittent ther modilution, the bolus will be rejected. 
i. If more than 1 result is greater than 15% of the mean or the prespecified rejection criteria 
is met, discard the entire series, and repeat the series of four thermodilutions. 
o Note: The likely cause for 2, 3 or 4 results being greater than 15% of the mean is technique dependent, i.e., shooting the thermodilution either fast, slow or drawing up 
the incorrect amount of fluid. 
ii. If none the results are greater than 15% of the mean or the prespecified rejection criteria 
is not met, discard one result that is furthest from the mean. 
x FloTrac and ClearSight will also display Pulse rate.  If Pulse varies > 15% during the 30-sec period of 
each ITD, the bolus will be rejected. 
i. If more than 1 result is greater than 15% of the mean or the prespecified rejection criteria 
is met, discard entire series, and repeat the series of four thermodilutions. o Note: The likely cause for 2, 3 or 4 results being greater than 15% of the mean is technique dependent, i.e., shooting the thermodilution either fast, slow or drawing up 
the incorrect amount of fluid. 
ii. If none the results are greater than 15% of the mean or the prespecified rejection criteria 
is not met, discard one result that is furthest from the mean. 
x ClearSight will display Physiocal.  If Physiocal is no t at least 30 beats, the bolus will be rejected.  
 
For Cardiac Output comparisons of FloTrac and ClearSight  to Swan-Ganz ITD, all hemodynamic monitors will be 
time aligned.    The CO values from ClearSight and FloTrac for the analyses will be prepared as follows:   
 
x Determine the averaging window corresponding with each bolus injection  
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 7 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
 
x Average the CO over the 30 second period  
 x Determine the average of 3 of 4 CO values 
 
The CO values from Swan-Ganz ITD for analyses will be prepared as follows: 
 
x Determine the CO from each of the 3 of 4 accepted bolus injections  
 
x Determine the average of 3 of 4 CO values 
 
 The CO values from Swan-Ganz ITD for analyses will be prepared as follows: 
x Determine the CO from each of the 3 of 4 accepted bolus injections 
x Determine the average of 3 of 4 CO values 
 
2.3 Sample Size Consideration 
 
2.3.1 Sample size consideration for bias 
 
The bias between the matched pairs of CO measurements, as determined by the Bland-Altman method, must be 
ƐŵĂůůĞƌ ƚŚĂŶ ƚŚĞ ŵŝŶŝŵƵŵ ĐůŝŶŝĐĂů ĚŝĨĨĞƌĞŶĐĞ ɷ͕ ǁŚŝĐŚ ŝƐ ƚŚĞ ǀĂůƵĞ ƚŚĂƚ ŝƐ ůĂƌŐĞ ĞŶŽƵŐŚ ƚŽ ĐůĂŝŵ ĚŝĨĨĞƌĞŶĐĞ͘ The 
hypothesis for bias is: 
 
  H0:  bias <- ɷŽƌďŝĂƐхɷ  
  H1: -ɷчďŝĂƐчɷ  
 
H0 is the null hypothesis (i.e. the difference between matc hed pairs of CO values of the two systems is larger than 
ɷͿ͕ ,ϭŝƐƚŚĞĂůƚĞƌŶĂƚŝǀĞŚǇƉŽƚŚĞƐŝƐ;ŝ͘Ğ͘ƚŚĞĚŝĨĨĞƌĞŶĐĞ ďĞƚǁĞ ĞŶŵĂƚĐŚĞĚ ƉĂŝƌƐŽĨ KǀĂůƵĞƐŽĨƚŚĞƚǁŽ ƐǇƐƚĞŵƐŝƐ
ǁŝƚŚŝŶƚŚĞƌĂŶŐĞŽĨɷͿ͘ ŵĞƚĂ -analysis conducted a comprehensive search of 21 published medical literature to 
assess the accuracy and precision of minimally-invasive CO  monitoring systems used in children when compared 
with CO monitoring reference methods [8]. Among the 21 studies, 19 studies (90%) showed a bias range of -0.5 to 
0.5 L/min. Based on ƚŚĞƐĞĚĂƚĂ͕ƚŚĞĐůŝŶŝĐĂůŵŝŶŝŵƵŵĚŝĨĨĞƌĞŶĐĞɷǁĂƐƐĞƚĂƚϬ͘ϱ>ͬ ŵŝŶ͕ŝ͘Ğ͘ďŝĂƐŝƐĞǆƉĞĐƚĞĚƚŽďĞ
-0.5< bias < 0.5 l/min. This value is smaller in magnitude than the 0.8 l/min floor that the US FDA had previously 
considered for CO comparisons. The me ta-analysis also shows that 19 out of  21 published studies had standard 
deviation (SD) no more than 1.0 L/min.   
 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 8 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
In this study eight repeated measurements (m=8 sub samples) or sub sample sections will be taken during the 
cardiac catherization case, thus intra-cl uster correlation ecoefficiency ICC is a factor to be considered in sample 
size estimation. Here ܥܥܫ= ఋೞమ
ఋೞమାఋೞೞమ. ߜ௦ଶis the variance component of study subject. ߜ௦௦ଶis the variance component 
of sum sample. By literature the ICC in children ranges from 0.94 to 0.98. The variation of study subject is dominant. 
Fixed the study subjects, the more sub-samples taken the less ߜ௦௦ଶwill be by a factor 1/m. This will reduce the total 
variance applied in sample size calculation. Using ICC=0.98, and SD=1 (Variance=1) as an example, for m=8,  the 
stand deviation used in sample size estimation is ܦܵ=ට0.98כ1+ଵି଴ .ଽ଼
଼=0 . 9 9 1 2 1 1 . 
 
The sample size calculation for this hypothesis is base d on the one-sample t-test for equivalence. The desired 
outcome is to reject the null hypothesis at the 0.025 si gnificance level. For this equivalence test of bias, two 
comparisons will be performed: FloTrac vs Swan-Ganz and ClearSight vs Swan-Ganz.  In order to preserve the 
overall type 1 error rate at 0.05, the Bonferroni Correction will be used to adjust for multiple comparisons.  
ƐƐƵŵŝŶŐ Ă ƚƌƵĞŵĞĂŶ ďŝĂƐŽĨ Ϭ͘Ϭ ĂŶĚ Ă ^ŽĨ ϭ͘Ϭ ůͬŵŝŶ ŝŶ ƚŚĞĐ ĂƌĚŝĂĐ ŽƵƚƉƵƚ͕ ƚŚĞ ƐĂŵƉůĞ ƐŝǌĞ ƌĞƋƵŝƌĞĚĨŽƌɷсϬ͘ϱ͕
alpha=0.025, and power=90% to reject the null hypothesis is 45, ignoring the ICC.  After considering ICC for eight 
repeated measures (m=8), adjusting for multiple compar isons, considering comparisons of between two target 
devices and a reference device pairs, simultaneously, a sample size of 60 Subjects is needed. After considering a 34.5% rejection rate for hemodynamic instability, 10% lost to  follow-up rate, and 6 roll-in Subjects for the learning 
curve, up to 108 (102) evaluable Pivotal Subjects and 6 Roll-in Subjects) will be enrolled into the study.  
 
By simulating the study resu lts with a mixed effect model, using repe ated measurement data collected from a 
similar study, although the sample size estimate from this  approach is conservative, it is reasonable and rational. 
 
2.3.2 Sample size consideration for percent error  
 
The Critchley and Critchley method of percent error (PE) calculation will be compared to 30%. The Precision will 
be considered as acceptable if PE is less than or equal to 30%.  The hypothesis for PE is a one-sided test:  H0: PE > 30% 
,ϭ͗WчϯϬй  
 
In a meta-analysis paper published in 2010, Peyton and Chong suggested that acceptable agreement should be a percentage error of 30% or less, which has become a widely quoted criterion.  
 
In a paper published by Odor, Bampoe, and Cecconi, “PE is calculated by dividing the limits of agreement by the 
mean value of measurements taken using the reference method of CO monitoring in the required population. A 
WĐƵƚŽĨцϯϬйŚĂƐďĞĞŶƐƵŐŐĞƐƚĞ d as a pragmatic guide for clinicians to determine whether a new measurement 
technique represents a good alternative to the reference standard. The basis of this approach is that the level of 
precision should be at least equivalent to the reference standar Ěŝ͘Ğ͘ƚŚĞƌŵŽĚŝůƵƚŝŽŶ͕ǁŚŝĐŚŝƐцϮϬй͘^ŝŶĐĞƌĂŶĚŽŵ
ĞƌƌŽƌŝŶŵĞĂƐƵƌĞŵĞŶƚŝƐĐŽŵƉŽƵŶĚĞĚĚƵƌŝŶŐĐŽŵďŝŶĂƚŝŽŶŽĨƚǁŽƉƌ ĞĐŝƐŝŽŶƐ͕ ǁŝƚŚ ƚǁŽ ŵĞĂƐƵƌĞŵĞŶƚƐ Ăƚ цϮϬй
ĞƋƵĂƚŝŶŐƚŽĂƚŽƚĂůĞƌƌŽƌŽĨцϮϴ͘ϯй͕ƚŚĞƚŽƚĂůWŝƐĐŽŵŵŽŶůǇ ƌŽƵŶĚĞĚƚŽцϯϬй͘dŚƵƐ͕ĨŝŶĚŝŶŐĂƉĞƌ centage error 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 9 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
ŽĨ ůĞƐƐ ƚŚĂŶ цϯϬй ĞƋƵĂƚĞƐƚŽ ƚŚĞ ŶĞǁ ƚĞƐƚĞĚ ƚĞĐŚŶŝƋƵĞ ŚĂǀŝŶŐ Ă Ŷ ĞƌƌŽƌ ƐŝŵŝůĂƌƚŽ ƚŚĞ ƌĞĨĞƌĞŶĐĞ ƐƚĂŶĚĂƌĚ͕ ǁŚŝĐŚ
should therefore be considered acceptable.” 
 
The sample size calculation for this hypothesis was based on the one-sided T-test. The desired outcome is to reject the null hypothesis at the 0.025 significance level. Assuming a true mean of 30% and a conservative SD assumption 
of 70%, the sample size required for power=90% to reject the null hypothesis is 49.  With Bonferroni adjustment for two comparison between three target device sy stems, enrollment of 60 subjects is required.  
 Additionally, in the paper "A meta-analysis of studies usin g bias and precision statistics to compare cardiac output 
measurement techniques,” Critchley LA and Critchley JA constructed an error gram from the percentage errors 
from the test and reference methods to determine acceptable limits between methods. They graphically showed 
that limits of agreement of up to +/-30% were acceptable for PE.  
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 10 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
Because the study is designed with sub samples (repeated measurements) or sub sample sections (m=8), ICC is a 
factor needing to be considered in the sample size esti mation. By similar assumption and calculation in section 
2.3.1, for m=8, the SD=69.38%, the corresponding sample size necessary is 49. For PE, a sample size of n=60 will 
be used in the study design, after considering two pairwise comparisons between 2 devices with a reference 
device.  In addition, after considering a, 34.5% rejectio n rate for hemodynamic instability, 10% lost to follow-up 
rate, up to 102 evaluable subjects will be targeted. To acco unt for the learning curve, 6 additional roll-in subjects 
will be enrolled (up to 3 at each site), tota ling 108 Subjects enrolled in the study.  
 2.3.3 Sample size consideration for bias calculated with cardiac index 
 
The bias between the matched pairs of CI measurements, as determined by the Bland-Altman method, must be ƐŵĂůůĞƌƚŚĂŶƚŚĞŵŝŶŝŵƵŵĐůŝŶŝĐĂů ĚŝĨĨĞƌĞŶĐĞɷ͕ǁŚŝĐŚŝƐƚŚĞǀĂ ůƵĞƚŚĂƚŝƐůĂƌŐĞĞŶŽƵŐŚƚŽĐůĂŝŵĚŝĨĨĞƌĞŶĐĞ͘  
 
The hypothesis for bias is: 
  H0:  bias <- ɷŽƌďŝĂƐхɷ  
  H1: -ɷчďŝĂƐчɷ  
 
Because there are no valid publications found through inte rnet searching to design th e settings in sample size 
estimation based on CI, the relation between CI and CO is used in sample size estimation here. Cardiac index (CI) 
is defined as cardiac output (CO)/body surface area (BSA).  By the results from Cattermole G. N., Leung P. Y. M., Mak P. S. K. et al. 2010 and Cattermole G. N., Leung P. Y. M., Ho G. Y. L. et al. 2017, the BSA value for kid with age 
൒8 is greater than 1, target on Chinese population in Hong Kong.  For the age group from 12 to 18 years, it is 
around 1.5. If the study subjects are from developed coun try the BSA value possibly will be larger. If the study 
targets at developing country population, this value possibly will be smaller. By this consideration BSA=1.2 is used 
in bias adjustment and the SD adjustment. The SD used in sample size estimation for CI will be 0.85 ( ܦܵ
஼ூൎௌ஽಴ೀ
஻ௌ஺ൎ
0.85 ).  
 
In this study eight repeated measurements or sub sample sections for each study subject will be taken during the 
cardiac catherization case, thus intra-clust er correlation ecoefficiency ICC is a factor to be considered in sample size 
estimation. Here ܥܥܫ= ఋೞమ
ఋೞమାఋೞೞమ. ߜ௦ଶis the variance component of study subject. ߜ௦௦ଶis the variance component of sum 
sample. By literature the ICC in children ranges from 0.94 to 0.98. The variation of study subject is dominant. Fixed 
the study subjects, the more sub-samples taken the less ߜ௦௦ଶwill be by a factor 1/m. This will reduce the total 
variance applied in sample size calculation. Using ICC=0.98 , and SD=1 (Variance=1) as an example, as an example, 
for m=8, the adjusted variance will be 0.98כ0.7225 + (1െ0.98 )כ଴.଻ଶଶହ
଼= 0.70985  and the SD=0.8425. 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 12 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
 
3. STUDY ENDPOINTS  
 
The primary effectiveness endpoint is to demonstrate that monitoring of cardiac output (CO) with Swan-Ganz, 
FloTrac, and ClearSight is comparable as determined by the Bland-Altman method of bias.   
 The secondary endpoint analyses will include: 
x CO, assessed using include using the Critchley and Critchley method of percent error calculation 
 
Two comparisons will be performed for each of three endpoints described above: FloTrac vs Swan-Ganz and 
ClearSight vs Swan-Ganz.    
 The primary and secondary efficacy endpoints will be analyzed  using the evaluable analysis set as defined in Section 
5.  
 
The primary safety endpoint is to assess all serious intr aoperative and post-operative adverse events through 30 
days, including serious device-related ev ents. The safety endpoint will be analyz ed using the safety analysis set as 
defined in Section 5.  
  
3.1 Primary effectiveness endpoint 
 
By the CO measurement from Swan-Ganz, FloTrac, and ClearSig ht, and Fick principle, the variable bias (X) is derived 
for statistical analysis: 
 
 ݔ
௜௝=ܱܥ௧௜௝െܱܥ௥௜௝ 
 
Where ݔ௜௝ is the bias of ݄ݐ݅ subject and ݄ݐ݆ matched pair repeated measurements, ܱܥ௧௜௝ is CO measurement of 
the ݄ݐ݅ subject at ݄ݐ݆ repeated measurement of test device, such as  Swan-Ganz, FloTrac, and ClearSight, ܱܥௗ௜ is 
the CO measurement of ݄ݐ݅ subject at ݄ݐ݆ repeated measurement of refe rence device the Swan-Ganz 
thermodilution pulmonary catheter. Here ݅=1 , … ,݊( the estimated sample size, 102), ݆= 1 ,….,݉(  the planned 
repeated measurements, 8).  
3.1.2 97.5% Confidence Intervals for bias using bootstrap and limit of agreement methods 
 
Bootstrap method will be used to estimate two-sided 97.5% confidence intervals for all CO and CI bias measures under study. This will be performed for all analysis datasets  as well as those data with rejected data. Results will 
be compared.  
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 13 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
 
3.2 Secondary effectiveness endpoints 
ܧܲ௜௝=1 0 0כหܱܥ௧௜௝െܱܥ௥௜௝ห
ܱܥ௥௜௝=1 0 0כหݔ௜௝ห
ܱܥ௥௜௝ 
3.2.1 PE derived by CO 
 
The percent error is derived as follow: 
 
ܧܲ௜௝=1 0 0כหܱܥ௧௜௝െܱܥ௥௜௝ห
ܱܥ௥௜௝=1 0 0כหݔ௜௝ห
ܱܥ௥௜௝ 
 
where ܧܲ௜௝ is the  percent error of ݄ݐ݅ subject at ݄ݐ݆ repeated measurement of FloTrac and ClearSight with CO 
measurements from the Swan-Ganz thermodilution pulmonary catheter, as the reference.  
 
3.3 Explatory analyses 
  
3.3.1 Bias derived by CI 
 
By the CI measurement from Swan-Ganz, FloTrac, and ClearSight, the variable bias (X) is derived for 
statistical analysis: 
 
ݔ௜௝=ܫܥ௧௜௝െܫܥ௥௜௝=(ܱܥ௧௜௝െܱܥ௥௜௝)/ܣܵܤ 
 
Where ݔ௜௝ is the bias of ݄ݐ݅ subject and ݄ݐ݆ matched pair repeated measurements of CI, ܫܥ௧௜௝ is CI 
measurement of the ݄ݐ݅ subject at ݄ݐ݆ repeated measurement by FloTrac and ClearSight, ܫܥ ௥௜௝ is the CI 
measurement of ݄ݐ݅ subject at ݄ݐ݆ repeated measurement of reference device, Swan-Ganz ITD, on the 
same study subject. Here ݅=1 , … ,݊( the estimated sample size, 102), ݆= 1 ,….,݉( the planned repeated 
measurements, 8). And ܣܵܤ  is the body surface area of this study subject. 
 
ܧܲ௜௝=1 0 0כหܱܥ௧௜௝െܱܥ௥௜௝ห
ܱܥ௥௜௝=1 0 0כหݔ௜௝ห
ܱܥ௥௜௝ 
3.3.2 PE derived by CI 
 
The percent error of CI is derived as follow: 
ܧܲ௜௝=1 0 0כหܫܥ െܫܥ ௥௜௝ห
ܫܥ௥௜௝=1 0 0כหݔ௜௝ห
ܫܥ௥௜௝=1 0 0כฬܱܥ௧௜௝
ܣܵܤെܱܥ௥௜௝
ܣܵܤฬ
ܱܥ௥௜௝
ܣܵܤ=1 0 0כඃܱܥ௧௜௝െܱܥ௥௜௝ඇ
ܱܥ௥௜௝ 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 14 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
where ܧܲ௜௝ is the  percent error of CI measurement of ݄ݐ݅ subject at ݄ݐ݆ repeated measurements by FloTrac and 
ClearSight, using Swan-Ganz ITD CI measurement as the reference. ܣܵܤ  is the body surface area of this study 
subject. Here the PE calculated by CI is the same as calc ulated by CO. Therefore, this fact will be noted and present 
in the final report.        
   
                        ݔ௜௝=ܱܥ௧௜௝െܱܥ௥௜௝ 
 
3.4 Explatory analyses 
 3.4.1 98.75% Confidence Intervals for PE using bootstrap method (derived by CO and CI)  
 
Bootstrap method will be used to estimate one-sided confidence for PE, CO and CI measures under study. This will 
be performed for all analysis datasets as well as those datasets with rejected data . Results will be compared. 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DI SCLOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC.  
DOC -0089208 Rev. A (T his template is required by DOC -0089205)   
  
Revision Date: December 2, 2020   
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 15 
Title Statistical Analysis Plan for A Prospective, Single- Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
4. ANALYSIS  POPULATIONS  
 
The analysis set is composed of all evaluable subjects with valid CO matched pair ed measurements from 
the target medical device system ( Swan -Ganz ™, FloTrac ™, and ClearSight ™), the Fick principle  and the 
reference medical device system  (a Swan- Ganz thermodilution catheter) .  Evaluable subjects are those  
with non-rejected intermittent thermodilutions  who have completed the 30 -day telephone follow up period.  
 
5. DEFINITIONS  
 
5.1. Enrolled Subject  
 
A subject will be considered enrolled in the study once the subject has signed the informed consent, 
a Swan- Ganz catheter has been deployed, a FloTrac has been connected, a ClearSight finger cuff 
has been attached and/or ForeSight Elite sensors have been placed.  
 
5.2. Evaluable Subject  
 
An evaluable subject is one who has valid CO pair measurements  that were not rejected  and also 
has completed the 30 -Day follow up . 
 
5.3. Modified Intent -to-treat (mITT)  
 
Modified Intent -to-treat (mITT) is defined as the study subjects who were exposed to the study 
product and will therefore be included in the effectiveness and safety analysis dataset s.   
 
5.4. Per Protocol Analysis  
 A per protocol analysis is defined as a  datas et of subjects who completed the cardiac catherization  
as written in the protocol.  No protocol deviations  occurred  during the cardiac catherization 
procedure.  
  
5.5. Pivotal Cohort  
 
The pivotal cohort are  subjects who were enrolled after the roll-in period.  The pivotal cohort will be 
analyzed separately from the roll- in cohort . 
  
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DI SCLOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC.  
DOC -0089208 Rev. A (T his template is required by DOC -0089205)   
  
Revision Date: December 2, 2020   
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 16 
Title Statistical Analysis Plan for A Prospective, Single- Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
5.6. Roll-in Cohort  
 
The roll -in cohort are the first 1- 3 subjects enrolled at the site that the study investigator uses to 
confidently perform the intermittent thermodilution. This group of patients will analyze separately 
from the pivotal subjects.  
 
5.7. Screen Failure  
 
A screen failure is a study subject  who does not meet all inclusion criteria or fails at least one of 
exclusion criteria . 
 
6. DATA AND ANALYSIS CONVENTIONS  
 
6.1 General Conventions 
 
The baseline characteristics and demographics of each study subject will be collected during the 
subject screening process.  The subject’s medical historical data will be recorded on an electronic case report form (eCRF).  The CO measurement data will be downloaded from hemodynamic monitor (Hemosphere advanced monitoring platform).  The Roll-in cohort data will be analyzed 
separately.  
 The data analyses will be conducted with SAS 9.4 software system. Bland Altman analyses will be performed for bias and precision measures. Limits of agreement will be calculated. 
 
6.2 Handling of Missing Data  
 
Missing data are defined as those instances in which data collection was attempted yet failed for 
some reason (i.e. due to technological, procedural, and/or subject constraints). Demographic and baseline characteristics are collected from the study subjects as part of screening.  If missing data are not related to the subject’s eligibility criteria, missing data will be presented by the valid sample size in the demographic and baseline characteristics summary statistics table.  Subjects with 
missing data will be included in the final analysis.  However, if the missing data are related to the 
subject’s eligibility, this will be considered a protocol deviation, and in this case, the study data from this subject will be reviewed internally, to determine if the subject should be excluded f rom the final 
analysis set.  
 The CO measurements  are downloaded from the hemodynamic monitor. Theoretically, there should 
be no missing data. For data that are missing as defined above,  statistical imputation using the SAS 
imputation method will be utiliz ed.   
 
6.3 Handling of Invalid  Data  
 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 17 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
After downloading the data from the hemodynamic monitors, abnormal observations will be checked 
and evaluated for hemodynamic stability.   Should there be any instability, the result will be rejected.  
All data will be recorded, and any rejected values will be clearly identified in the eCRF.  
 
The rejection criteria that will be used to determine - hemodynamic instability are detailed below: 
x Mean arterial pressure (MAP):  If MAP varies > 15% during the 30-sec period of each 
intermittent thermodilution, the bolus will be rejected. 
x Pulse rate:  If Pulse varies > 15% during the 30-sec period of each ITD, the bolus will be 
rejected. 
x PhysioCal:  If PhysioCal is not at least 30 beats, the bolus will be rejected. 
x  
Upon taking four (4) thermodilution measurements and given the above criteria for classifying data 
as invalid, Edwards proposes to remove the one measurement that is the greatest outlier of the 
four.  If upon the rare occasion two or more outliers measure greater than 15% from the mean, 
within a series of measurements, or hemodynamic instability results when these observations are taken, the clinician will repeat the series.  If this scenario of repeating the series is missed by the 
clinican during the clinical procedure and discove red by the statisticians during data review, the 
outliers will be analyzed separately. In addition to the results for the collected parameters, the 
number of subjects with less than 3 and number of subjects with at least 3 valid values, and 
results of subjects will be tabulated separately, and reported.  Those subjects who have less than 
3 valid measurements and were missed for repeated testing by the clinician performing the 
thermodilutions will be considered as protoc ol deviations or pr otocol violations.  
Additionally, a supplementary exploratory analysis will be reported using all the recorded values 
(valid and invalid) to assess the impact of the excluded values. 
 
7. SUMMARY OF BASELINE INFORMATION 
 
7.1 Subject Eligibility Criteria 
 Inclusion Criteria  
1. Subjects who are 12 to 18 years of age 
2. Subjects who have signed the Informed Consent Form 
3. Subjects who are projected to receive Swan-Ganz catheter as part of procedure/standard of care with 
intermittent cardiac output measures  
4. For those Subjects who have had a cardiac transplant, Subjects must be at least two weeks post   cardiac transplantation Subjects     
5. Subjects with planned pressure monitoring with an arterial line   
   Exclusion Criteria  
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 18 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
1. Subjects with contraindications for Pulmonary Artery Catheters Placement and monitoring (recurrent 
sepsis, or with hypercoagulopathy); 
2. Subjects with contraindications for Arterial Line Placement; 
3. Subjects with an extreme contraction of the smooth muscle in the arteries and arterioles in the lower arm and hand (i.e., Raynaud’s Disease). 
4. Subjects with a physical site area too limited for proper Sensor placement 
5. Subjects with finger size less than the smallest finger cuff size 
6. ŽĐƵŵĞŶƚĞĚшŵŽĚĞƌĂƚĞƉƵůŵŽŶĂƌǇŚǇƉĞƌƚĞŶƐŝŽŶ;WWŵхϮϱŵŵ,Ő͕W sZ/хϯ͘ϬthǆŵϮͿ  
7. Presence of intracardiac shunting (i.e., ASD, VSD) 
8. Aorto-pulmonary collaterals  
9. шDŽĚĞƌĂƚĞƚƌŝĐƵƐƉŝĚƌĞŐƵƌŐŝƚĂƚŝŽŶ͕ƉĞƌĞĐŚŽĐĂƌĚŝŽŐƌĂŵĐƌŝƚĞƌŝĂ  
10. > Moderate Aortic or pulmonary regurg itation, per echocardiogram criteria 
11. Persistent cardiac arrythmias during the cardiac catheterization period (> 3min) 
12. Vascular abnormalities of the arterial system (i.e., connective tissue disorder s, mid-aortic syndrome)” 
 
 
7.2 Demographics and Baseline Characteristics 
 
The baseline characteristics and demographics of each  study subject will be collected during the subject 
screening process.   
 
7.3 Medical History 
 
The subject’s medical historical data will be recorded on an electronic case report form (eCRF).  The CO 
measurement data will be downloaded from hemo dynamic monitor (Hemosphere advanced monitoring 
platform). 
 
7.4 Risk Assessments 
 
Any events associated with a commercially available st udy device will be reported in accordance with the 
Medical Device Reporting (Complaints) regulation (2 1 CFR Part 803), while events associated with the 
investigational device will be reported  under the IDE program (812.150). .  
 
Below is a list of anticipated risks that may be associated with the use of Swan-thermodilution pulmonary 
artery catheter. 
 
x Perforation of the pulmonary artery 
x Pulmonary infarction 
x Cardiac arrhythmias 
x Knotting 
x Sepsis/Infection 
x Right bundle branch block 
x Complete heart block 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 19 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
x Tricuspid and pulmonic valve damage 
x Thrombocytopenia 
x Pneumothorax 
x Thrombophlebitis 
x Nitroglycerin absorption 
x Thrombosis 
x Allergic reaction to latex 
 
FloTrac sensor 
The vascular access obtained is standard clinical care and the addition of the FloTrac arterial transducer is 
standard procedure and does not impose any additional ri sk to the patient. There is no measurable increased 
infectious risk with the temporary use of the FloTtrac sensor.  
Below is a list of anticipated risks that may be asso ciated with the use of the ClearSight finger cuff. 
x Discomfort where the cuff is applied 
x Discoloration of digit distal to the cuff 
x Pain associated with inflation of the cuff 
x Slight numbness of the fingertip 
 Below is a list of anticipated risks that may be associated with the use of ForeSight Elite Sensors. 
x Allergic reaction to sensors 
x Skin irritation 
 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 21 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
8.  STATISTICAL ANALYSIS OF STUDY ENDPOINTS 
 
8.1 Primary Endpoint  
 
The primary objective of this study is to demonstrate that monitoring of cardiac output with Sawn-Ganz, 
FloTrac, and ClearSight is comparable as determined by the Bland-Altman method of bias. To demonstrate 
this comparability, the bias calculation will be assessed separately. 
 
Summary statistics and statistical comparison 
 
The CO measurements from both investigational and reference device systems will be summarized using 
descriptive statistics including mean, median, minimum, maximum, standard deviation, Q1 (first quantile), 
and Q3 (third quantile).  Additionally, p values from pa ired t-test will be provided to test the difference.  
 
8.1.2 Primary endpoint analysis with Bias calculated by CO  
The primary endpoint of the bias between the matched pairs of CO measurements as determined by the Bland-
Altman method will be tested as below using the one sample t-test.  
 
The hypothesis for bias is: 
 
H0:  bias <-0.5 or bias >0.5  
H1: -Ϭ͘ϱчďŝĂƐчϬ͘ϱ  
See section 3.1 for details. 
 
8.1.3 Limits of Agreement  
Limits of agreement will be computed using Bland-Altm an methods. Components of  the one-way analysis of 
variance will be used to estimate variance of multiple  between-device differences for the same subject. These 
components of variance meas ures include the mean square for subjects (SS), and residual mean square (RMS). 
The differences between the average difference across subjects will be estimated from the difference between 
SS and RMS.  This difference will be divided by M=;;є mi)2 - є m i2)/(n-1)*( єmi), where n = total number of 
subjects, and m i is the number of pairwise difference measurements for the  ŝƚŚ subject. The estimated 
component of variance, which represents the heterogeneity, is estimated as (SS – RMS)/M. The total variance (TV) for single differences on different subjects is es timated by the sum of these two components: TV = (SS – 
RMS)/M + RMS. The resulting lower and upper limits of  agreement will be estimated with 97.5% confidence 
mean(diff) ± 1.984*TV for a two-sided test. 
 
 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 22 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
We want agreement to be the same or at least similar over the range of CO and CI measurements. Plots of the 
difference bias between device pairings (ClearSight vs Swan-Ganz, and FloTrac vs Swan-Ganz), for CO and CI 
measurements, on average of the two device measurements  will be performed, with reference lines including 
zero, mean difference, and lower and upper limits of ag reement. Two-sided 97.5% LOA will be calculated for 
bias between device pairings9. The statisticians will determine whethe r the standard deviation of the mean 
difference is constant or non-constant for each measure. The mean difference and standard deviation about the mean difference will be estimated for all measurements. The difference measures will be tested for 
heterogeneity using components of variance methods. The variance for single differences  between device pairs 
of measurements, on different subject, will be plotted. Also, mean difference will be plotted on the order in which observations are recorded for each subject.  
 
Visual check of the bias spread pattern and deviation us ing scatter plots of bias and/or percent error versus 
Fick principle reference mean CO, and scatter plot of bias and the percent error versus target device mean CO, 
with reference lines zero and limits of agreement  ( ߜ͟ߜߜ to the plot will be performed.  
 
8.2  Secondary Endpoint  
 
8.2.1 Percent Error calculated by CO as the secondary endpoint 
The secondary endpoint of the percent error between the matched pairs of CO measurements as 
determined by the Critchley and Critchley method will be tested as below using the one sample t-test.  The hypothesis for PE is: 
 
H0: PE > 30% ,ϭ͗WчϯϬй  
 
 
8.3 Sensitivity Analysis 
 
8.3.1  Sensitivity analysis on study subject To determine the effectiveness of stud y subject on the analytical results, following sensitivity analysis will  
be conducted by artificially removing one or a few study subjects. The expected result is that no study  subject or group of study subjects are influence subjects on the analytical result.    
8.3.2 Sensitivity analysis on reference device 
To determine the effectiveness of reference device on the test device in the analytical results, different reference devices will be applied in sensitivity analys is. The expected result is that the reference device 
performance is stable and consistency, which is no t the influence factor for the analytical result. 
 
8.4 Exploratory Analyses 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 23 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
The following exploratory analyses will be preformed 
x Comparison analysis of CI calculated for Bias as determined by Bland Altman method with 
confidence intervals.  
x Comparison analysis of CI as determined by th e Critchley and Critchley method of percent error 
calculation with confidence intervals 
x Subgroup analysis of primary and secondary endpoint by age stratification 
x Subgroup analysis of primary and secondary endpoint by gender 
x Subgroup analysis of primary and secondary endpoint by race 
x Subgroup analysis of primary and secondary endpoint by site 
x Comparison of cardiac output from FloTrac, ClearSight and Swan-Ganz technologies to the Fick 
principle 
 
   8.4.1 Validation of Accuracy and Consistency 
Considering the variation of CO measurement from both device systems among patients, applying patient and 
patient age group as potential classification factors, the conclusion from 8.1.2 will be validated with bootstrap 
method through the 97.5% coverage intervals, which should be within the range from - ߜ to ߜ  .These analyses 
will be presented within clinical study report.   
   8.4.2 Variance component analysis 
 With mixed effect model, the derived variable bias as the response, study site, surgery team, and subject as the random variable, estimate the variance component of each factor to trace the main source of variability, 
which will benefit to future variation control. This analysis will be present in the clinical study report. 
 
 
8.5 Interim analysis 
No interim analysis is planned for this study.  
 
8.6 Analysis of other hemodynamic parameters 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DI SCLOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC.  
DOC -0089208 Rev. A (T his template is required by DOC -0089205)   
  
Revision Date: December 2, 2020   
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 24 
Title Statistical Analysis Plan for A Prospective, Single- Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
 Below is a table of other hemodynamic parameters measures that will be collected in this study.  
Table 1. Measures by Device and Endpoint  
 Device   
Parameters  Swan 
Ganz  FloTrac  ClearSight  ForeSight  Endpoints  
Cardiac Output (CO)  X X X  Primary  (Bland Altman) , 
Secondary (Percent Error)  
Cardiac Index (CI)  X X X  None (exploratory analyses - 
descriptive stats)  
Central Venous Pressure 
(CVP)   X   None (exploratory analyses - 
descriptive stats)  
Diastolic Blood Pressure 
(DIA(ART)/DIA(PAP))   X   None (exploratory analyses - 
descriptive stats)  
Dynamic Arterial 
Elastance (Ea(dyn))   X X  None (exploratory analyses - 
descriptive stats)  
Intermittent cardiac index 
(iCI) X    None (exploratory analyses - 
descriptive stats)  
Intermittent cardiac 
output (iCO)  X    None (exploratory analyses - 
descriptive stats)  
Intermittent systemic 
vascular resistance (iSVR)  X    None (exploratory analyses - 
descriptive stats)  
Intermittent systemic 
vascular resistance index 
(iSVRI)  X    None (exploratory analyses - 
descriptive stats)  
Mean Arterial Pressure 
(MAP)   X X  None (exploratory analyses - 
descriptive stats)  
Mean pulmonary artery 
blood pressure (MPAP)   X   None (exploratory analyses - 
descriptive stats)  
Noninvasive Arterial 
Diastolic Pressure 
(DIA(NI))    X  None (exploratory analyses - 
descriptive stats)  
"Noninvasive arterial 
systolic blood pressure 
(SYS(NI))"    X  None (exploratory analyses - 
descriptive stats)  
Pulmonary artery diastolic 
blood pressure (DIA(PAP))   X   None (exploratory analyses - 
descriptive stats)  
Pulmonary artery systolic 
blood (SYS(PAP))   X   None (exploratory analyses - 
descriptive stats)  
Pulse Pressure Variation 
(PPV)   X X  None (exploratory analyses - 
descriptive stats)  
Pulse Rate (PR)  X X X  None (exploratory analyses - 
descriptive stats)  
Stroke volume (SV)  X X X  None (exploratory analyses - 
descriptive stats)  
Stroke volume index (SVI)  X X X  None (exploratory analyses - 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DI SCLOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC.  
DOC -0089208 Rev. A (T his template is required by DOC -0089205)   
  
Revision Date: December 2, 2020   
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 25 
Title Statistical Analysis Plan for A Prospective, Single- Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
Table 1. Measures by Device and Endpoint  
descriptive stats)  
Stroke Volume Variation 
(SVV)   X X  None (exploratory analyses - 
descriptive stats)  
Systemic arterial diastolic 
blood pressure (DIA (ART))   X   None (exploratory analyses - 
descriptive stats)  
Systemic arterial systolic 
blood pressure (SYS(ART))   X   None (exploratory analyses - 
descriptive stats)  
Systemic vascular 
resistance (SVR)   X X  None (exploratory analyses - 
descriptive stats)  
Systemic vascular 
resistance index (SVRI)   X X  None (exploratory analyses - 
descriptive stats)  
Systolic Pressure 
(SYS(ART)/SYS(PAP))   X   None (exploratory analyses - 
descriptive stats)  
Systolic Slope (dP/dt)   X X  None (exploratory analyses - 
descriptive stats)  
StO2 - 1 (cerebral)     X None (exploratory analyses - 
descriptive stats)  
StO2 - 2 (cerebral)     X None (exploratory analyses - 
descriptive stats)  
 
 
9 ANALYSIS OF SAFETY  
9.1 Adverse  Events  
 
The adverse events data will be summarized with frequency counts and percentages. The 
frequency distribution and percentage of  adverse event related to a specific medical device will be 
presented.  The primary safety endpoint will include summar y of intraoperative and post- operative  
adverse events, discharge through 30 days followup,  related or unrelated to the devices under 
study.   
 
9.2 Deaths and Other Serious Adverse Events  
   
Death or other serious adverse events that occur during this study  will be summarized with  
frequenc ies and percentages.  
 
 
10 CHANGES FROM PROTOCOL SPECIFIED ANALYSES 
  
There are no changes to the protocol specified analyses at this time.  
  
THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DI SCLOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC.  
DOC -0089208 Rev. A (T his template is required by DOC -0089205)   
  
Revision Date: December 2, 2020   
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 27 
Title Statistical Analysis Plan for A Prospective, Single- Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
12 APPENDIX  
13 LITERATURE SEARCH/REVIEW  
 
For the original FloTrac submission in 2004 and the publication (Nusmeier, van Der Hoeven, and 
Lemson, 2010), an abstract search was performed to compile relevant clinical data on the accuracy 
and acceptance criteria of various injectate and continuous car diac output measurements (iCO, and 
CCO). PubMed was searched using the keywords “continuous” OR “Fick’ OR pulse contour" OR “TD”) AND "cardiac output" AND “precision”, to identify published literature that reported performance 
comparisons of cardiac output  measurements. A total of 97 abstracts of published articles were found 
as a result of the search.  
 Review of the abstracts showed that 42 of them were irrelevant. Of the 42 that were not taken into 
consideration, 17 reported on pre -clinical studies, 21 had insufficient statistics and 4 did not provide 
performance comparison of cardiac output. Hence, 55 abstracts were deemed relevant to this 
analysis. Ten out of 55 abstracts reported accuracy in terms of cardiac index. The remaining 45 
abstracts contained 75 pairs of Bland- Altman comparisons. Fourteen of the 75 Bland- Altman 
comparison pairs were reported as marginal or unacceptable, the remaining 61 pairs from 38 abstracts were reported as clinically acceptable [32 -69].  
 
Figure 1 indicates a histogram of the bias reported in the 61 comparisons. The range of bias reported 
as clinically acceptable was [ -0.79 …0.63]. However, from the histogram, it can be seen that only 
three of the reported values were outside +/ - 0.6 l/min. Thus, the literature advocated out er limits of 
+/- 0.6 l/min for the bias of a Bland- Altman comparison of cardiac output values.  
 
Since then, several CO validation studies against pulmonary and transpulmonary thermodilution with 
the noninvasive technology have been performed. The analysis of 10 of these studies [70- 79] showed 
a bias range of 0.0 to 0.6 L/min, with an average of 0.24 ± 0.19 L/min. Based on these data and after 
discussion with the Data Management and Bio- center of the National Center for Cardiovascular 

THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION OF EDWARDS LIFESCIENCES, LLC. IT MUST NOT BE REPRODUCED OR DISC LOSED TO 
THIRD PARTIES WITHOUT PRIOR WRITTEN PERMISSION OF EDWARDS LIFESCIENCES, LLC. 
DOC-0089208 Rev. A (This template is required by DOC-0089205)  
  
Revision Date: December 2, 2020  
Rev  
B For Use Only by 
Affiliates of 
Edwards 
Lifesciences  
Page 28 
Title Statistical Analysis Plan for A Prospective, Single-Arm, 
Nonrandomized, Observational Study  of Cardiac Output 
Monitoring in Pediatric Patients  
 
 
Diseases (Professor Wei LI), the performance criterion was set at 0.5 L/min, i.e. bias is determined to 
be -0.5< bias < 0.5 l/min. This value is smaller in magnitude to the 0.8 l/min floor that the US FDA had 
previously considered for CO comparisons.  
 
14 PEER REVIEW REQUEST, PER SAP INSTRUCTION (DOC-0089205)  
 
Yes Name of Reviewer: No Reason Peer Review not Needed: 
;   ܆  
 
